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Abstract 
 
        Natural products play important roles in the survival of organisms, and provide a 
large pool of candidates for drug discovery and pharmaceutical investigations. A major 
class of peptide-based natural products are ribosomally synthesized and post-
translationally modified (RiPPs). Lanthipeptides, which possess (methyl)lanthionine 
structures, are a class of intensively studied RiPPs. Based on the biosynthesis enzymes 
that introduce the thioether motifs, lanthipeptides are classified into four classes. Class I 
lanthipeptides utilize two distinct enzymes, a dehydratase and a cyclase, while class II 
lanthipeptides adopt a bifunctional enzyme. Trifunctional enzymes with independent 
evolution pathways are employed by class III and class IV lanthipeptides. A major 
subclass of lanthipeptides possess antimicrobial activity, known as lantibiotics with 
known modes of action including lipid II binding, pore formation, inhibition of spore 
outgrowth, and phosphatidylethanolamine (PE) binding. Several lanthipeptides display no 
antimicrobial activities but have other functions important for bacterial life cycles, such 
as facilitating aerial hyphae formation during sporulation.  
        In the past, most lanthipeptides were discovered based on their activity mainly 
through antimicrobial screening campaigns. With the advances in genome sequencing 
and bioinformatics, a variety of lanthipeptides have been identified by genome mining, 
presumably with more unexplored functions and molecular targets. Prochlorosins are an 
unusual group of lanthipeptides, which were discovered through genome mining and 
have no known antibiotic activities. Further biological function investigations of 
prochlorosins require pure products in adequate amounts, which was not achievable 
iii 
 
through natural product isolation or in vitro enzymatic assays. In this thesis, Chapter 2 
describes the development of a novel co-expression system to produce prochlorosins by 
in vivo enzymatic modification in E. coli, providing prochlorosins with high purity and 
sufficient quantity for subsequent characterizations. Chapter 3 presents an example of 
utilizing the co-expression methodology to produce antimicrobial lanthipeptides, with 
additional modifications besides dehydration and cyclization. The precursor peptide of 
actagardine, one of the only two lantibiotics that have been evaluated in clinical trials 
thus far, was fully modified in E. coli as presented in Chapter 3. A luciferase-like 
monooxygenase located in the biosynthetic cluster of actagardine was also reconstituted, 
both in vitro and in vivo, to introduce a sulfoxide group onto actagardine and its 
derivatives. Based on the success of in vivo co-expression of lanthipeptides with 
identified or unidentified activities, Chapter 4 describes efforts towards the incorporation 
of non-canonical amino acids into lanthipeptides, in order to expand the structural 
diversity of these natural products, tune their activities, and introduce probes for 
subsequent functional investigations. The work presented in this thesis provides methods 
to effectively produce the peptide-based natural products lanthipeptides, in adequate 
quantities for subsequent investigations including study of substrate peptides and their 
modification enzymes, peptide structure elucidation, as well as sequence and structure 
diversification.  
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CHAPTER 1: LANTHIPEPTIDES: BIOSYNTHESIS AND 
MODES OF ACTION 
 
1.1 INTRODUCTION 
        Natural products are chemicals produced by living organisms for a variety of 
reasons during their life cycles. These compounds play important roles for the survival of 
organisms, such as defending against pathogens,
1
 inhibiting the growth of competitors,
2
 
functioning as signaling molecules for communication,
3
 or as by-products of 
metabolism.
4
 Because of their diversified activities, natural products have supplied a 
large pool of candidates for drug discovery,
5
 inspiring the development of antimicrobial,
6
 
anticancer,
7
 antimalarial,
8
 and anti-HIV drugs.
9
 The development of genome sequencing 
and bioinformatic studies have revealed that a major class of peptide-based natural 
products are ribosomally synthesized and post-translationally modified that have recently 
been named RiPPs (as an abbreviation for Ribosomally synthesized and Post-
translationally modified Peptides).
10
 The biosynthetic pathways of RiPPs are designated 
as Post-Ribosomal Peptide Synthesis (PRPS), as opposed to Non-Ribosomal Peptide 
Synthesis (NRPS), which produce natural products through modular assembly.
10
 
        Extensive modifications have been introduced into RiPPs through PRPS, such as 
methylation,
11
 dehydration,
12
 amidation,
13
 hetero- or macro-cyclization,
14
 glycosylation,
15
 
epimerization,
14
 and aromatization.
16
 With the introduction of structures not accessible 
with the canonical 20 amino acids, these modifications have not only significantly 
expanded the chemical diversity of the RiPPs and increased their functionality and 
2 
 
bioactivity, but also augmented their stability by restricting their conformations and 
protecting the peptides against proteolysis.  
        RiPPs are encoded as a precursor peptide in the genome, typically with a length of 
20 – 110 amino acid residues.10 These precursor peptides generally contain an N-terminal 
leader peptide and a C-terminal core peptide. The leader peptides serve multiple proposed 
functions during the maturation of the final products, including: 1) serving as docking 
molecules recognized by the biosynthetic enzymes to initiate modification, 2) facilitating 
precursor-peptide folding during the modifications, and 3) protecting the producing 
strains from their bioactive final products by keeping the modified core peptide in an 
inert state inside the cells.
17
 Some precursor peptides possess an extra short sequence 
attached N-terminally to the leader peptide known as a signal peptide, directing the 
precursors to their subcellular locations for certain post-translational modifications.
18
 
Some precursor peptides append a so-called recognition sequence attached C-terminally 
Figure 1.1 General biosynthesis scheme of RiPPs. Most RiPP precursor peptides contain a 
leader peptide N-terminally attached to the core peptide, except bottromycin for which the 
leader peptide is attached C-terminally to the core peptide.  
 
3 
 
to the core peptide for product excision and cyclization (Figure 1.1).
19
 Noteworthy, the 
precursor peptide of bottromycin lacks an N-terminal leader peptide but contains a long 
sequence attached C-terminally to the core peptide with functions similar to the leader 
peptide. Such a C-terminal sequence is designated as a “follower” peptide.20  
 
1.2 LANTHIPEPTIDES: DEFINITION AND CLASSIFICATIONS 
          Lanthipeptides are a class of intensively studied RiPPs, with the name referring to 
lanthionine-containing peptides (formerly known as lantipeptides).
21
 They are 
characterized by unusual thioether linkages named lanthionine (Lan) and/or 
methyllanthionine (MeLan). Lanthipeptides are ribosomally synthesized as a linear 
precursor peptide generally with an N-terminal leader peptide and a C-terminal core 
peptide. Biosynthetic enzymes catalyze the dehydration of some or all of the serine (Ser) 
and threonine (Thr) residues in the core peptide to 2,3-didehydroalanine (Dha) and (Z)-
2,3-didehydrobutyrine (Dhb) moieties, respectively. Cysteine residues from the core 
peptides then undergo intramolecular Michael addition onto these α, β-unsaturated amino 
acids, forming (methyl)lanthionine rings catalyzed by biosynthetic enzymes. Besides the 
aforementioned dehydrated residues and thioether crosslinks, post-translational 
modifications have also introduced diversified functional groups into lanthipeptides, 
including but not limited to D-amino acid residues (as in lactocin S and lacticin 3147),
22
 
lysinoalanine (as in cinnamycin),
23
 sulfoxide (as in actagardine),
24
 disulfides (as in 
bovicin HJ50),
25
 N-terminal acetylation (as in paenibacillin),
26
 carbon-carbon crosslink 
(as in labyrinthopeptin A2),
27
 and hydroxylated and halogenated amino acids (as in 
microbisporicin) (Figure 1.2).
28
 
4 
 
        Based on the biosynthetic enzymes that introduce the thioether motifs, 
lanthipeptides are classified into four classes (Figure 1.3). The dehydration of precursor 
peptides in class I is catalyzed by a dehydratase generically named LanB, while the 
cyclization is catalyzed by a dedicated LanC cyclase.
29
 LanC enzymes possess conserved 
residues forming a Cys-Cys-His triad by binding to a zinc ion in the active site.
29,30
 The 
bound zinc activates the Cys thiols in the LanA peptide for nucleophilic attack onto the 
Dha or Dhb residues formed by LanB catalysis.
29,30
 A transmembrane ATP-binding 
cassette (ABC) transporter LanT encoded in the biosynthetic gene cluster facilitates the 
Figure 1.2 Representative structural motifs introduced by post-translational modifications 
into lanthipeptides. Lanthipeptides are featured by dehydroalanine, dehydrobutyrine, and/or 
(methyl)lanthionine structures. Other diversified motifs are also observed occasionally.  
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export of modified precursor peptides from the cytosol. Often the class I biosynthesis 
pathway also possesses a dedicated subtilisin-like serine protease LanP. The protease 
either is anchored in the cell membrane or resides in the cytoplasm and is responsible for 
removing the leader peptide from the modified core peptide to generate the final 
bioactive compound. The most intensively studied lanthipeptide nisin, an antimicrobial 
natural product produced by Lactococcus lactis, is a typical class I lanthipeptide. The 
nisin precursor peptide NisA is dehydrated and cyclized by NisB and NisC, respectively 
(Figure 1.4). Recent pull-down experiments using C-terminally His-tagged NisA 
Figure 1.3 Four classes of lanthipeptide synthetases responsible for the generation of 
dehydrated amino acid residues and (methyl)lanthionine structures. Dark lines represent the 
conserved residues in the enzymes that are important for their catalytic activities.  
6 
 
discovered that NisB and NisC form a complex during NisA modification in L. lactis.
31
 
An ABC transporter NisT encoded between nisB and nisC in the nisin biosynthetic gene 
cluster transports the modified precursor peptide before the proteolytic removal of the 
leader peptide by NisP.
21
 The epilancin 15X protease ElxP was recently reported as the 
first in vitro reconstituted protein in the LanP family.
32
 
       
        Class II lanthipeptides undergo the dehydration and cyclization with the help of a 
bifunctional enzyme, generically named LanM (Figure 1.5), which has an N-terminal 
dehydratase domain with no homology with LanB proteins, and a C-terminal LanC-like 
cyclase domain.
12
 ATP and Mg
2+
 are required for the LanM to perform phosphorylation 
of the Ser/Thr residues and subsequent phosphate ester elimination to generate Dha/Dhb, 
(NisB) 
(NisC) 
(NisP) 
Figure 1.4 Class I lanthipeptide biosynthesis pathway as represented by the maturation of nisin. 
 
Nisin 
7 
 
as originally demonstrated by in vitro study of the lacticin 481 synthetase LctM.
12,33
 
Interestingly, no ATP binding site was found in LctM and no ATP is required for the 
LctM-catalyzed cyclization to occur.
34
 Class II lanthipeptides, such as lacticin 481,
12
 
lacticin 3147,
35
 mersacidin,
36
 actagardine,
24
 and haloduracin,
37
 utilize one dedicated 
LanM synthetase to modify one precursor peptide substrate in nature. However, recent 
genome-mining studies have identified novel class II lanthipeptide biosynthesis systems 
where one LanM synthetase possesses much higher substrate tolerance than previously 
recognized, such as a single synthetase ProcM encoded with 29 potential substrates in the 
Lacticin 481 
Figure 1.5 Class II lanthipeptide biosynthesis pathway as represented by the maturation of 
lacticin 481. The bifunctional enzyme LanM catalyzes both the dehydration and cyclyzation 
processes. Besides transportation, the ABC-transporter LanT also removes the leader 
peptide through proteolysis. 
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cyanobacterium Prochlorococcus MIT9313.
38
 More details about the ProcM system is 
provided in Chapter 2. Leader peptide removal and secretion of class II lanthipeptides is 
facilitated by ABC-transporter LanT proteins, which typically contain an N-terminal 
papain-like cysteine protease domain that is not present in class I LanT transporters.
39
  
        In Class III lanthipeptides, the dehydro amino acids are introduced through 
phosphorylation of Ser/Thr residues by a kinase domain in a synthetase generically 
named LanKC, followed by the elimination of the phosphate by a phosphoSer/Thr lyase 
domain located at the N-terminus of the LanKC.
40
 Similar as LanM, the LanKC protein 
also contains a C-terminal cyclase motif but without the zinc-binding residues conserved 
among LanC-like cyclase domains.
27
 The first discovered LanKC enzyme was RamC 
which catalyzed the production of the morphogenetic peptide SapB in Streptomyces 
coelicolor.
41-43
 LabKC was later found as an analog of RamC, which catalyzes the 
synthesis of labyrinthopeptins in Actinomadura namibiensis, employing GTP instead of 
ATP to function in vitro.
44,45
 Many LabKCs also catalyze the formation of a carbon-
carbon crosslink termed labionin (Lab), a structure exclusively found in class III 
lanthipeptides, presumably formed by Michael attack onto a dehydroalanine by the 
enolate generated during the formation of thioether linkages (Figure 1.6). However, the 
mechanism of LabKC catalysis of this second Michael addition is still elusive.
46
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        Class IV lanthipeptide synthetases, generically named LanL, also encompass an N-
terminal phosphoSer/Thr lyase domain and a central kinase domain. Unlike LanKC, 
LanL proteins bare a C-terminal LanC-like domain with conserved zinc-binding 
residues.
40
 The first report on LanL reported in vitro reconstitution of a synthetase from 
Streptomyces venezuelae called VenL. In the presence of ATP and Mg
2+
, VenL 
performed phosphorylation, phosphate elimination, and cyclization on the VenA 
substrate.
40
 Remarkably, both class III and class IV lanthipeptide biosynthetic gene 
clusters contain LanT-like proteins without a protease domain, while no proteases have 
been found in these clusters so far. Although LanM, LanKC, and LanL all catalyze 
dehydration through phosphorylation and elimination, no kinase or lyase domain has 
been found in LanM. In fact, LanB/C, LanM, LanKC and LanL are grouped into different 
clades in phylogenetic analysis, suggesting independent evolution pathways of these 
modification enzymes.
47
 
Figure 1.6 Biosynthetic pathway to labionin. 
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1.3 LANTHIPEPTIDE BIOACTIVITY AND MODES OF ACTIONS 
          A major subclass of lanthipeptides display antimicrobial activity, and are called 
lantibiotics (abbreviation of lanthionine-containing antibiotics). Thus far, more than 60 
lantibiotics
21
 have been identified and characterized out of more than 90 known 
lanthipeptides.
10
 Elucidated lantibiotic modes of action fall into four major groups:  
        (i) Inhibition of bacterial cell wall biosynthesis via binding to lipid II. Lipid II is a 
membrane-anchored intermediate for bacterial cell wall biosynthesis.
48
 Lipid II facilitates 
cell wall biosynthesis by transferring peptidoglycan subunits from the cytoplasm to the 
outside of the cell membrane, where the peptidoglycan units are assembled into a 
peptidoglycan sheet that forms the skeleton of the bacterial cell wall. Lipid II is 
composed of a polyisoprenoid anchor, attached to two sugar subunits, one N-
acetylglucosamine (GlcNAc) and one N-acetylmuramic acid (MurNAc)-pentapeptide, via 
a pyrophosphate linker.
49
 Nisin,
50
 mutacin 1140,
51
 subtilin,
52
 mersacidin,
53,54
 epidermin,
55
 
and actagardine
53
 are known to inhibit peptidoglycan polymerization by binding to lipid 
II. The N-terminal two rings of nisin bind to the pyrophosphate moiety of lipid II, 
forming a pyrophosphate cage.
56
 Mersacidin and actagardine were suggested to bind to 
the disaccharide-diphosphate region,
57
 unlike the glycopeptide antibiotic vancomycin 
which binds to the C-terminal dipeptide region (D-Ala-D-Ala) of the pentapeptide part of 
lipid II.
58
  
        (ii) Pore formation in the cell membrane. Utilizing bound lipid II as a docking 
molecule, nisin is able to form pores in the cell membrane with its three C-terminal rings, 
each pore consisting of eight nisin molecules and four lipid II molecules.
48
 Pore 
formation was also observed with gallidermin against Micrococcus and Staphylococcus 
11 
 
strains but not with Lactococcus lactis, suggesting the thickness of the target bacterial 
cell membrane and the length of the lantibiotics determine the mode-of-action of certain 
lantibiotics, as shorter peptides may not be able to span across the bacterial cell 
membrane to form pores, while lipid II binding is less affected by the lantibiotic 
lengths.
55
  
        Recently discovered two-component lantibiotics require two peptides (named as the 
- and -peptides) that synergistically display full activity. Individual  or  peptides 
possess little to no antimicrobial activity. Currently known two-component lantibiotics, 
such as haloduracin,
37
 plantaricin W,
59
 lacticin 3147,
60
 and cytolysin,
61
 are all class II 
lanthipeptides modified by LanM synthetases. As a typical two-component lantibiotic, 
haloduracin  (Hal) binds to lipid II, facilitating the pore formation by haloduracin 
Halin the cell membrane through a lipid II-Hal-Hal complex in a 1:2:2 
stoichiometry.
62,63
 Ring-topology elucidation
64
 and mutagenesis of haloduracin,
63
 
together with NMR study of lacticin 3147
60
 and sequence alignments revealed that the -
peptides bear three C-terminal rings homologous to mersacidin, which are important for 
lipid II binding activity.
65
 
       (iii) Inhibition of the outgrowth of spores. Nisin and subtilin were observed to inhibit 
spore outgrowth of Bacillus and Clostridium species.
66
 The activity was abolished when 
their Dha5 was substituted by alanine, while the bactericidal activity was not affected.
21,67
 
However, when the Dha5 was substituted by phenylalanine, neither activity was 
abolished. Meanwhile, the removal of the C-terminal region (nisin Δ23 – 34) resulted in 
the decline of both activities.
68
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        (iv) Other modes of actions. Duramycin and its close structural analogue cinnamycin 
inhibit phospholipase A2 by binding to phosphatidylethanolamine (PE) in the cell 
membrane.
69-71
 Nisin and Pep5 were also shown to interact with the teichoic acids on the 
cell membrane to induce autolysis of several staphylococcal strains.
72
  
        According to intensive investigations on nisin and duramycin resistant strains, 
resistance to lantibiotics include the change of membrane components, rigidification of 
the cell membrane, thickening of the cell wall, alteration of the hydrophobicity of the cell 
wall, and tuning of cell membrane electronic potential.
21,73,74
 These resistant mechanisms 
are consistent with known modes of action of lantibiotics, which mainly target the cell 
membrane components in the course of cell wall biosynthesis. A series of genes, such as 
the histidine kinase gene lisK, the high molecular-weight penicillin binding protein gene 
pbp2229, the histidine protein kinase gene hpk1021, and the D-alanine-poly 
(phosphoribitol) ligase subunit gene dltA were shown to be involved in the alteration of 
membrane compositions.
21
 However, genetic alterations of target bacteria upon 
incubation with lantibiotics have not been comprehensively studied, which may unravel 
more detailed explanations of resistant phenotypes and underexplored modes of actions. 
        Several lantibiotics such as epilancin K7
75
 and epilancin 15X
76
 permeabilize the cell 
membrane through pore formation without binding to lipid II.
62,75
 However, their modest 
pore formation ability and highly potent antimicrobial activity suggest that unknown 
targets are yet to be explored. Besides toxicity against bacteria, cytolysin, a two-
component lantibiotic, exhibits hemolytic activity by unexplored mechanisms.
77
  Some 
lanthipeptides exhibit no significant antimicrobial activity but have other functions. 
These compounds include SapB, a morphogenetic peptide produced by Streptomyces 
13 
 
coelicolor; AmfS, a SapB homolog secreted by S. griseus; and SapT produced by S. 
tendae, all facilitating aerial hyphae formation during sporulation.
42,78,79
 In the past, most 
lanthipeptides were discovered based on their activity mainly through antimicrobial 
screening. The recently discovered prochlorosins through genome mining have displayed 
neither growth inhibitory effect against common soil bacteria nor other common 
activities,
38
 suggesting the roles of these lanthipeptides are still to be discovered. With the 
development of sequencing technologies, bioinformatics and high-throughput analysis, 
hundreds of lanthipeptides have been identified in the genomes, presumably with more 
currently unknown biological functions and molecular mechanisms.
47,80-83
 
 
1.4 SUMMARY AND OUTLOOK 
        Natural products play important roles in the survival of organisms, and provide a 
large pool of candidates for drug discovery and pharmaceutical investigations. A major 
class of peptide-based natural products are ribosomally synthesized and post-
translationally modified. Lanthipeptides which possess (methyl)lanthionine structures are 
a class of intensively studied RiPPs. Based on the biosynthesis enzymes that introduce 
the thioether motifs, lanthipeptides are classified into four classes. Class I lanthipeptides 
utilize distinct dehydratase LanB and cyclase LanC, while class II lanthipeptides adopt a 
bifunctional enzyme LanM. Trifunctional enzymes LanKC and LanL are employed by 
class III and class IV, respectively. A major subclass of lanthipeptides possess 
antimicrobial activity, known as lantibiotics with known modes of action including lipid 
II binding, pore formation, inhibition of spore outgrowth, and phosphatidylethanolamine 
(PE) binding. 
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        Several lanthipeptides display no antimicrobial activities but other functions 
important for bacterial life cycles, such as facilitating aerial hyphae formation during 
sporulation. With the development of genome mining and bioinformatics, a variety of 
lanthipeptides have been identified in the genome, presumably with more unexplored 
functions and molecular targets. Prochlorosins are a typical group of lanthipeptides which 
were discovered through genome mining without known antibiotic activities. Further 
biological function investigations of prochlorosins require pure products in adequate 
amounts, which was not achievable through natural product isolation or in vitro 
enzymatic assays. In this thesis, Chapter 2 will describe the development of a novel co-
expression system to produce prochlorosins by enzymatic modification in E. coli, 
providing prochlorosins with high purity and sufficient quantity for subsequent bio-
function characterizations. Chapter 3 will present use of the co-expression methodology 
to produce antimicrobial lanthipeptides, with extra modifications besides dehydration and 
cyclization. The precursor peptide of actagardine, one of the only two lantibiotics that 
have been evaluated in clinical trials thus far, was fully modified in E. coli as presented in 
Chapter 3. A luciferase-like monooxygenase located in the biosynthetic cluster of 
actagardine was also reconstituted, both in vitro and in vivo, to introduce a sulfoxide 
group onto actagardine and its derivatives. Based on the success of in vivo co-expression 
of lanthipeptides with known or unidentified activities, Chapter 4 will describe efforts 
towards the incorporation of non-canonical amino acids into lanthipeptides, in order to 
expand the structural diversity of these natural products, tune their activities, and 
introduce probes for subsequent functional investigations. 
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CHAPTER 2: IN VITRO AND IN VIVO RECONSTITUTION 
OF THE BIOSYNTHESIS OF PROCHLOROSINS
1
 
 
2.1 INTRODUCTION 
        Based on genome mining using the mersacidin synthetase gene mrsM from Bacillus 
sp. strain HIL Y-85 as a query, a single novel lanM-like gene was found by previous 
graduate student Dr. Bo Li in the genomes of two closely related strains of 
Prochlorococcus (MIT9313 and MIT9303) and one distantly related strain of marine 
Synechococcus (RS9961). Interestingly, the genome of Prochlorococcus MIT9313 also 
contains 29 putative lanA-like genes as potential substrates of its single LanM-like 
protein. A smaller number of potential substrates are encoded in the genomes of 
Prochlorococcus MIT9303 and Synechococcus RS9961. Thus, Prochlorococcus 
MIT9313 was chosen as a subject of the following investigation.         
        Prochlorococcus is a planktonic marine cyanobacterium that distributes widely 
throughout the world, from the surface waters to the deep ocean.2 This ubiquitous 
photosynthetic prokaryote has a special significance as the smallest known 
photosynthetic organism, maintaining its diverse biofunctions with a limited genome size  
(e.g. 2.4 Mbp for the genome of Prochlorococcus MIT9313).3,4 The genomes of  
 
1Reproduced in part with permission from: "Production of lantipeptides in Escherichia coli" J. 
Am. Chem. Soc. 2011, 133, 2338-2341. Copyright 2010 American Chemical Society. 
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Prochlorococcus strains collected from different oceans of the world and different depths 
in the ocean are remarkably diverse, which is presumably due to their adaptability to exist 
in a variety of niches. Studies on the importance of this genetic variation and the stimuli 
that induced the variation are still under way.3 Prochlorococcus is found as a ubiquitous 
organism in the nutrient-poor regions of the ocean, which suggests that it may have 
special features for surviving under nutrient-limiting conditions that are unfavorable for 
most other marine organisms.5 
The lanM-like gene in Prochlorococcus MIT9313 was designated as procM, while 
the lanA-like genes were designated as procAs.6 Seven procAs are localized in the same 
gene cluster as procM (procA1.1 - procA1.7), with 20 other procAs organized in three 
additional clusters within the same Prochlorococcus genome (procA2.1 - procA2.11, 
procA3.1 - procA3.5, procA4.1 - procA4.4). Two more isolated procA genes were found 
elsewhere in the genome (procAs.1 and procAs.2).6 The translated sequences of procA 
genes have high homology in their leader peptide regions but their core peptide 
sequences are strikingly diverse (Figure 2.1). The putative leader and core regions of 
ProcA peptides are separated by a Gly-Gly or Gly-Ala sequence that is usually present in 
class II lanthipeptide precursor peptides7 and is generally a cleavage site of an ABC-
transporter with an N-terminal cysteine protease domain, which removes the leader 
peptide and secretes the mature core peptide. The mature core peptides were designated 
as prochlorosins (Pcn).6 
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The discovery of 29 genes encoding LanA-like peptides with only one gene 
encoding a LanM protein in the Prochlorococcus genome is of great interest, suggesting 
substrate tolerance of ProcM. The highly diverse core peptides of the 29 ProcAs have no 
homology to any known lanthionine-containing compounds, which in turn would 
significantly enlarge the pool of existing lanthipeptide structures. As the cell density of 
the plankton in the ocean is relatively low, especially the nutrient depleted areas where 
Figure 2.1 Amino acid sequence alignment of twenty-nine ProcA precursor peptides. Highly 
conserved residues in the leader peptides are highlighted in blue. Serine and threonine residues 
in the core peptides are highlighted in orange and pink, respectively. Cysteine residues are 
highlighted in green. The arrow indicates putative cleavage sites to remove the leader peptides 
after modification in nature. 
 
Leader peptide Core peptide 
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Prochlorococci dominate, prochlorosins may have antibiotic activity or may work as 
signaling molecules.6 
Among the 29 genes coding for prochlorosins, five (procA1.1, 1.7, 2.5, 3.3 and 4.3) 
have been shown to be transcribed in exponentially growing Prochlorococcus MIT9313 
cultures in ocean water, while the others have not yet been analyzed.6 ESI-MS analysis of 
solid phase extractions of the supernatant from the cultures identified detectable levels of 
Pcn2.1, 2.11, and 3.2.6 In order to perform further structural and biofunctional 
investigations, production of a relatively large amount of prochlorosins in the laboratory 
was needed. In vitro production of the peptides is one route towards this goal because less 
than 10 µg of unpurified prochlorosins could be obtained from a 20 L Prochlorococcus 
culture cultivated in ocean water.6 For in vitro production, genes encoding ProcAs and 
ProcM were amplified from Prochlorococcus MIT9313 genomic DNA, followed by 
insertion into the appropriate vectors and utilizing Escherichia coli for heterologous 
expression. A former group member, Dr. Bo Li, accomplished the cloning of 16 of the 29 
procA genes into the pET15b vector and the procM gene into the pET28b vector. In 
addition, some preliminary work, including detailed bioinformatics studies and ring 
topology investigations, was performed by Dr. Li in collaboration with the group of 
Professor Sallie Chisholm at the Massachusetts Institute of Technology.6 This chapter 
describes the development of a new production method that involves co-expression of the 
ProcA precursor peptides with the ProcM enzyme in E. coli. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 ProcM dehydrates and cyclizes ProcAs and their mutants 
In addition to the procA/pET15b constructs prepared by Dr. Bo Li, two more procAs 
(procA2.4 and procA2.8) were cloned in this work from Prochlorococcus MIT9313 
genomic DNA into the pET15b vector. ProcA2.4, ProcA2.8 (for sequences, see Figure 
2.1), and ProcM were produced in E. coli with an N-terminal hexahistidine tag (His6) to 
allow convenient purification. At room temperature, peptides ProcA2.4 and ProcA2.8 
were incubated with ProcM in 50 mM HEPES buffer (pH 7.5) in the presence of 2.5 mM 
ATP, 10 mM MgCl2, and 0.5 mM tris(2-carboxyethyl)phosphine (TCEP) for two days. 
Negative control reactions including ProcA and the other necessary components except 
ProcM were set up in parallel. After incubation, either endoproteinase Asp-N or Glu-C 
was added to the reaction mixture to remove a part of the leader peptide together with the 
His6-tag from the core peptide. The mixtures were incubated at room temperature for 5 h 
and then subjected to matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-ToF-MS) (for spectra, see Figure 2.2). After incubation with 
ProcM and Asp-N treatment, the proteolytic fragment containing the ProcA2.4 core 
peptide exhibited a molecular ion consistent with the loss of one molecule of water 
(calculated (calcd): 2655.22 [M – H2O + H
+], observed: 2654.91), while a small peak 
corresponding to the loss of two molecules of water was also observed (calcd: 2637.21 
[M – 2 H2O + H
+], observed: 2637.04). However, the majority of ProcA2.4 core peptides 
were not dehydrated as shown by MALDI mass spectrometry (Figure 2.2A). After 
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incubation with ProcM and Glu-C treatment, the loss of two molecules of water from the 
proteolytic fragment containing the ProcA2.8 core peptide was observed (calcd: 2392.97 
[M – 2 H2O + H
+], observed: 2393.03, see Figure 2.2B). Without ProcM treatment, no 
dehydrations were observed in the assay with either peptide. These observations establish 
Figure 2.2 In vitro dehydrations of ProcAs by ProcM analyzed by MALDI-ToF-MS. 
Representative MALDI-ToF mass spectra of ProcAs modified by ProcM after proteolytic 
cleavage using A) Asp-N for ProcA2.4, B) Glu-C for ProcA2.8, and C) TEV for 
ProcA3.2TEV. (D) Amino acids sequences of ProcAs after proteolytic cleavage. Cys 
residues are in red, and Ser/Thr residues that may be dehydrated are in blue. Underlined 
amino acids belong to the remaining part of the leader peptide after proteolytic cleavage. 
Unmodified peptides are denoted as M in the figure. 
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that ProcM is catalytically competent in dehydrating ProcA2.4 and ProcA2.8, with the 
latter being a better substrate. 
Previously, proteolytic cleavage of wild type ProcAs was not able to remove the 
leader peptides completely as none of the proteases used could cleave C-terminally at the 
Gly-Gly motif.6 In order to completely remove the leader peptide without cleavage of the 
core, specific protease cleavage sites were introduced via substitution of the C-terminal 
amino acid residues in the leader peptides. As a trial, the four C-terminal residues of the 
leader peptides of ProcA2.1, 2.11 and 3.2 (for wild type sequences, see Figure 2.1) were 
substituted with IEGR, which is the cleavage site for Factor Xa protease. Additionally, 
the six C-terminal residues of the ProcA2.11 and 3.2 leader peptides were also substituted 
with ENLYFQ, which is the tobacco etch virus (TEV) protease recognition sequence. The 
mutant peptides, designated ProcA2.1Xa, ProcA2.11Xa, ProcA2.11TEV, ProcA3.2Xa, 
and ProcA3.2TEV, were incubated with or without ProcM in 50 mM HEPES buffer (pH 
7.5) in the presence of 2.5 mM ATP, 10 mM MgCl2, and 0.5 mM TCEP for 15 to 20 h. 
After incubation, the products of the assays with ProcA2.1Xa, ProcA2.11Xa, and 
ProcA3.2Xa were treated with commercial Factor Xa, while the ProcA2.11TEV and 
ProcA3.2TEV products were treated with TEV protease. MALDI-ToF MS analysis was 
then applied to analyze the outcome of the assays. After TEV protease treatment, a peak 
corresponding to the loss of three molecules of water was observed for the ProcA3.2 core 
peptide (calcd: 2883.09 [M – 3 H2O + H
+], observed: 2881.74, see Figure 2.2C). The 
dehydration of ProcA3.2TEV was almost complete, with nearly all the core peptides fully 
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dehydrated (− 3 H2O), after incubation with ProcM at room temperature for 3 days. 
However, no dehydrations were observed in the spectra of the assay products of 
ProcA2.1Xa, ProcA2.11Xa, or ProcA3.2Xa, suggesting the mutations interfered with the 
modification by ProcM. For the reaction of ProcM with ProcA2.11TEV, no peaks 
corresponding to the ProcA2.11 core peptide were observed, with either sinapinic acid 
(SA) or α-cyano-4-hydroxycinnamic acid (CHCA) used as the MALDI matrix, although 
peaks corresponding to the leader peptide were observed. Hence, the in vitro approach 
was only partially successful as introduction of the protease cleavage sites appeared to 
hamper in vitro modification of the peptides by ProcM. Even though ProcA3.2TEV was 
successfully modified by ProcM, longer incubation time (3 days) was required to realize 
the completion of the modifications, compared with a much shorter time for the wild type 
ProcA3.2 (12 h).6 Therefore, multiple-amino-acid substitution at the C-terminus of the 
leaders of ProcA peptides may hinder the ProcM efficiency in vitro. 
 
2.2.2 Ring topology determination of modified ProcA core peptides 
        As the masses of cyclized and uncyclized derivatives of dehydrated ProcA peptides 
are identical, liquid chromatography electrospray ionization tandem mass spectrometry 
(LC/ESI-MS/MS) was adopted for further characterization of the modified ProcA core 
peptides (for spectra, see Figure 2.3). For modified ProcA2.4, no fragmentation was 
observed except in the sequence remaining from the leader peptide (Figure 2.3A). For 
modified ProcA2.8, two non-overlapping rings can be assigned to the core peptide made 
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by connecting Cys3 to Dha9 and Cys19 to Dha13, according to the fragmentation pattern 
observed in tandem mass spectrometry (Figure 2.3). 
Figure 2.3 In vitro cyclization patterns of ProcAs modified by ProcM shown by tandem 
mass spectrometry. Representative tandem mass spectra of ProcAs modified by ProcM after 
proteolytic cleavage using Asp-N for ProcA2.4 (A & B), and Glu-C for ProcA2.8 (C). (D) 
Fragmentation patterns of ProcAs after proteolytic cleavage as determined by tandem mass 
spectrometry. Red arrows indicate the b and y” ions in MSMS spectra. Core peptide 
sequences are in blue, the remaining leader peptide sequences in green. Putative 
dehydroalanines (Dha) and dehydrobutyrines (Dhb) are highlighted in green, cysteine 
residues highlighted in blue. For the ProcA2.4 fragment with only one dehydration, it is not 
certain which of the Ser and Thr was dehydrated, thus no Dhb or Dha is indicated in the 
sequence shown here. 
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For modified ProcA3.2 core peptide cleaved from ProcA3.2TEV, the fragmentation 
pattern was similar to that of ProcA3.2 produced in vivo by Prochlorococcus MIT9313 
(Figure 2.4), indicating that after incubation with ProcM and treatment with TEV 
protease, the ProcA3.2 core peptide was dehydrated and cyclized to give the same ring 
topology as Pcn3.2 produced by the producing Prochlorococcus MIT9313. 
 
 
Figure 2.4 ESI-MS/MS of ProcA3.2TEV modified by ProcM in vitro and treated by TEV 
protease. The fragment pattern is similar as Pcn3.2 detected in the culture of 
Prochlorococcus MIT9313 and wild type ProcA3.2 modified by ProcM in vitro, with the 
latter two reported in Reference 6. 
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2.2.3 One-vector co-expression of His6-ProcA and ProcM 
        As shown in the previous section, modified ProcA core peptides with the same ring 
topology as the corresponding prochlorosins produced in vivo by Prochlorococcus 
MIT9313 strains can be obtained via in vitro incubation of a linear precursor ProcA with 
ProcM. However, the in vitro method was not able to provide sufficient quantities of the 
prochlorosins for more detailed structural and biofunctional investigations. One major 
hurdle was the solubility of ProcA linear precursor peptides, which dissolve in aqueous 
buffer only in the presence of guanidine hydrochloride. The in vitro reactions of linear 
precursor ProcA and ProcM usually resulted in precipitation after incubation for more 
than 6 hours. Downstream high-performance liquid chromatography (HPLC) separation 
of the reaction supernatant was therefore only able to provide trace amount of purified 
modified core peptides. 
        It is known that engineering of lanthipeptides can be accomplished by manipulation 
of the sequence of the precursor peptides in host strains and heterologous expression 
systems8 as well as with in vitro reconstituted systems.9 The former methods have the 
advantage of potential scale-up, whereas the in vitro approach allows introduction of 
nonproteinogenic amino acids. Any improved variants identified by the in vitro method 
could in principle be produced in vivo using amber stop-codon suppression technology.10 
Unfortunately, at the outset of my studies this methodology is not available for most 
lanthipeptide expression hosts. To be able to take full advantage of in vivo introduction of 
nonproteinogenic amino acids, production of lanthipeptides in E. coli would be highly 
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desirable, but only a single such example has been reported to date for a truncated analog 
of the class II lantibiotic nukacin ISK-1.11 In order to try to improve the production of 
prochlorosins, a single vector co-expression method was adopted using the pRSFDuet-1 
vector. The genes encoding a series of ProcA peptides fused to an N-terminal His6-tag 
were cloned into multi-cloning site 1 (MCS1) of pRSFDuet-1, while the gene encoding 
ProcM without His6-tag was cloned into multi-cloning site 2 (MCS2). Each of the two 
genes was expressed under the control of the T7 promoter. E. coli BL21 (DE3) cells were 
transformed with the procA/procM/pRSFDuet-1 plasmid, and the transformants were 
cultured under conditions previously used for ProcM overexpression. Surprisingly, upon 
harvest and lysis of the cells, the peptides were mostly present in the soluble portion 
unlike the unmodified ProcA’s that are typically expressed in inclusion bodies. After 
purification by immobilized metal affinity chromatography (IMAC), the peptides were 
isolated in yields ranging from 10 to 35 mg per liter of culture. Remarkably, analysis of 
the products by MALDI-ToF MS showed that they had been fully modified by ProcM in 
E. coli. 
        In principle, the proteolytic removal of the leader peptides could be executed in vivo 
by introducing the genes encoding the ABC-transporter. However, in order to avoid the 
complications often encountered with heterologous expression of proteases and potential 
toxic effects of the final post-translationally modified products, artificial protease 
cleavage sites were introduced into the C-termini of ProcA leader peptides to allow for 
complete removal of the leader peptides in vitro. As an example, the glycine residue at 
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the C-terminus of the leader peptide of ProcA1.7 was substituted with an arginine 
affording ProcA1.7-G−1R (negative residue numbers are used for amino acids in the 
leader peptide counting backwards from the leader peptide cleavage site, while positive 
residue numbers are used for amino acids in the core peptide counting forward from the 
leader peptide cleavage site), allowing trypsin removal of the leader peptide. Similarly, 
procA2.11-G−1K, procA3.2TEV, and procA3.3-G−1K were also constructed and cloned 
into MCS1 of a pRSFDuet-1 vector with procM in MCS2.      
        After overexpression and purification by IMAC, the modified precursor peptides 
(for their wild type sequences, see Figure 2.1) were treated with the appropriate 
commercial proteases (trypsin for ProcA1.7-G−1R, Lys-C for ProcA 2.11-G−1K and 3.3-
G−1K, and TEV protease for ProcA3.2TEV). Dehydration of the peptides was confirmed 
by MALDI-ToF MS (Figure 2.5). Fragmentation patterns shown by tandem mass 
spectrometry confirmed the same ring topology of the prochlorosins modified by ProcM 
in E. coli as that of prochlorosins obtained in vitro and produced in vivo from 
Prochlorococcus MIT9313 (Figure 2.6, the modified peptides are denoted as “Pcn in E. 
coli”). 
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        To avoid unwanted cleavage within the modified core peptides, the protease 
cleavage sites described in the previous paragraph were chosen such that they were not 
present in the core peptide sequences. This consideration limited the pool of cleavage site 
candidates. However, even when a suitable artificial cleavage site could be identified, 
complete leader peptide removal was often not successful as will be discussed below. For 
example, when Arg-C was used in attempts to remove the leader peptide of 
Figure 2.5 MALDI-MS spectra of precursor peptides modified by ProcM in E. coli and 
treated with a protease to remove the leader peptide. A) ProcA1.7-G−1R treated by trypsin, 
B) ProcA2.11-G−1K treated by Lys-C, C) ProcA3.3-G−1K treated by Lys-C, and D) 
ProcA3.2TEV_Phe26pBpa (F26B) treated by TEV protease. Unmodified peptides are 
denoted as M in the figure. 
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ProcA1.7G−1R it failed to cleave C-terminally at the introduced arginine. Trypsin was 
able to perform the desired cleavage but also cleaved C-terminally at a lysine residue in 
the ProcA1.7 core peptide, producing significant amounts of side product. In order to 
avoid this problem, procA1.7-G−1E/procM/pRSFDuet-1 was constructed. Glu-C was 
used for leader peptide removal of this mutant in which Gly−1 of ProcA1.7 was 
substituted with a glutamic acid. However, Glu−6 was preferred by Glu-C over Glu−1 in 
ProcA1.7-G−1E and resulted in undesired cleavage. Similar results were observed with 
ProcA3.3-G−1E and ProcA4.3-G−1E. 
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Figure 2.6 ESI-MSMS of four ProcA peptides processed by ProcM in E. coli and cleaved by 
commercial proteases. A) Pcn1.7. B) Pcn2.11. C) Pcn3.2. D) Pcn3.3. E) Comparison of 
fragmentation patterns of Pcn2.11 obtained in vitro, in vivo from E. coli and from 
Prochlorococcus cultures. F) Fragmentation patterns of the four prochlorosins analyzed by 
ESI-MSMS. The N-terminal threonine of the ProcA1.7-G−1R core peptide is converted to 
dehydrobutyrine by ProcM. This dehydrobutyrine is hydrolyzed to a 2-oxobutyryl (Obr) group 
after trypsin cleavage at the cleavage site. Dehydroalanine (Dha) and dehydrobutyrine (Dhb) 
residues are highlighted in green. Red lines indicate the ring forming after ProcM 
modifications.6 Purple lines indicate putative ring topology after ProcM modifications.  
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        Besides the previously discussed procA mutants inserted in procM/pRSFDuet-1, 
procA2.1-G−1R, 2.1-G−1E, and 4.3-G−1R were also inserted into MCS1 of the 
procM/pRSFDuet-1 vector. For ProcA2.1 mutants, presumably because Cys1 in the core 
peptide is involved in forming a thioether ring, neither ProcA2.1-G−1R nor ProcA2.1-
G−1E was successfully cleaved by the corresponding proteinase to provide the intact 
modified core peptide. At present, the ring topology of ProcA2.1 core peptide after 
ProcM modification still needs to be confirmed, by either tandem MS or NMR 
spectroscopy. For ProcA4.3-G−1R, Arg−15 was the preferential cleavage position instead 
of Arg−1 (Figure 2.7), thus only small peaks corresponding to the intact modified core 
Figure 2.7 MALDI-MS spectrum of ProcA4.3-G−1R precursor peptides modified by 
ProcM in E. coli and treated with trypsin to remove part of the leader peptide. The 
unmodified peptide is denoted as M in the figure. 
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peptide were observed after trypsin cleavage, and the intact modified core peptide could 
not be purified using analytical HPLC. 
        In addition to the co-expression constructs described above, procA1.2-A−1K, 1.3-
G−1K, 1.4-G−1E, 1.5-A−1K, 1.6, 1.6-G−1R, 2.8-G−1K, 4.1TEV, 4.4-G−1E, and s.1-
G−1K were also cloned into MCS1 of procM/pRSFDuet-1 vector partially with the help 
of rotation students Caitlin Deane and Manuel Ortega. Peaks of expected intact fully 
Figure 2.8 MALDI-MS spectra of several precursor peptides modified by ProcM in E. coli 
and treated with a protease. A) ProcA1.2-A−1K treated by Lys-C, B) ProcA1.3-G−1K 
treated by Lys-C, C) ProcA1.5-A−1K treated by Lys-C, D) ProcA1.6 treated by Glu-C, E) 
ProcA2.8-G−1K treated by Lys-C, and F) ProcA4.1TEV treated by TEV protease. 
Unmodified peptides are denoted as M in the figure. 
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modified prochlorosins were detected in MALDI spectra after Lys-C cleavage of 
ProcA1.2-A−1K, 1.3-G−1K and 1.5-A−1K, Glu-C cleavage of ProcA1.6, Lys-C cleavage 
of ProcA2.8-G−1K, and TEV protease cleavage of ProcA4.1TEV (Figure 2.8). 
        In summary, the co-expression methodology worked remarkably well to produce 
tens of milligrams of modified ProcA peptides. However, the removal of the leader 
peptides proved challenging and required evaluation of various different strategies. 
Whereas successful solutions were found for some peptides, no generally applicable 
method was found. 
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2.2.4 Large scale prochlorosin preparation for bioactivity investigations 
        Fully modified prochlorosins for which the leader peptide could be successfully 
removed were purified by analytical reversed phase HPLC using a C18 column. The 
correct masses of the purified prochlorosins were confirmed by MALDI-MS as shown in 
Figure 2.9 MALDI-MS spectra of four prochlorosins modified by ProcM in E. coli after 
commercial protease cleavage and HPLC purification. A) Pcn1.7, B) Pcn2.11, C) Pcn3.2 and 
D) Pcn3.3. 
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Figure 2.9 and the purity of these prochlorosins is shown in Figure 2.10. Purified Pcn1.7, 
2.11, 3.2, and 3.3, as well as partially dehydrated ProcA1.7, 3.2 and 3.3 core peptides that 
were also purified by HPLC, have been sent to our collaborator Professor Sallie 
Chisholm’s group for bioactivity investigations performed by her graduate student Mr. 
Andres Cubillos. Partially dehydrated core peptides were also sent because the partially 
dehydrated peptides are also produced by Prochlorococcus MIT9313. Whether they play 
Figure 2.10 Analytical RP-HPLC of purified prochlorosins. A) Pcn 2.11, B) Pcn3.2, and C) 
Pcn3.3. 
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any roles in nature and whether they function independently or in combination with the 
fully dehydrated and cyclized products, is still to be explored.  
        Linear ProcA3.2 and ProcA2.11 core peptides mutants, with all the Cys residues 
substituted by Ser residues, were prepared by solid-phase peptide synthesis (SPPS) and 
sent to MIT as control compounds. The Cys to Ser substitutions were considered in order 
to exclude the possibility of non-enzymatic disulfide bond formation in complex 
experimental environments that would interfere with the desired linear control peptides. 
Other control compounds included modified ProcA1.7, 2.11, 3.2, and 3.3 precursor 
peptides (with leader peptides still attached), linear ProcA3.2 core peptide generated by 
TEV cleavage of unmodified ProcA3.2TEV, and representative lantibiotics nisin and 
epilancin 15X. Upon the addition of prochlorosins, the transcriptome of prochlorosin-
producing and non-producing strains will be analyzed in comparison with the controls, as 
a preliminary investigation of the biological function of prochlorosins.  
        Furthermore, fully modified ProcA2.8-G−1K and ProcA3.3-G−1K with a C-
terminal His6-tag (ProcA2.8-G−1K-His6 and ProcA3.3-G−1K-His6) instead of a His6-tag 
at the N-terminus were also prepared by in vivo co-expression. After proteolytic cleavage 
and purification, C-terminally His6-tagged Pcn2.8 and Pcn3.3 were generated and sent to 
Mr. Cubillos, for antibody conjugation or pull-down experiments to locate prochlorosins 
in situ and identify their interacting molecules. The samples that have been prepared and 
sent to Mr. Cubillos are listed in Table 2.1. 
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2.2.5 Incorporation of a non-canonical amino acid into modified ProcA 
        To introduce a photoaffinity labeling group to probe prochlorosin targets in vivo, an 
amber stop codon (TAG) was introduced into procA3.2TEV replacing the codon encoding 
Phe26. The mutant gene procA3.2TEV_F26B was co-expressed with ProcM from a 
pRSFDuet-1 vector, with an orthogonal tRNA/tRNA synthetase pair encoded in a pDule 
vector (obtained from Professor Peter G. Schultz of the Scripps Research Institute). This 
tRNA/tRNA synthetase pair was constructed to incorporate the photocrosslinking amino 
Table 2.1 Samples sent to MIT for bioactivity assays. 
Samples Amount / mg
Pcn1.7  2.6
Pcn2.11     3.7
Pcn3.2       7.3
Pcn3.3       7.1
Pcn1.7 w/ some ProcA1.7 core peptide −4 H2O 0.07
ProcA3.2 core −2 H2O 0.36
Pcn3.2 & ProcA3.2 core −2 H2O mixture 0.13
Pcn3.3 & ProcA3.3 core −2 H2O 0.08
linear ProcA2.11 core with cysteines substituted by serines   4.4
linear ProcA3.2 core with cysteines substituted by serines    9.2
linear wild type ProcA3.2 core peptide 0.27
Pcn2.8 with C-terminal His6-tag     2.1
Pcn3.3 with C-terminal His6-tag     1.6
Epilancin 15X 0.51
Nisin           0.24
ProcA1.7 modified precursor peptide 2.6
ProcA2.11-G−1K modified precursor peptide 1.2
ProcA3.2TEV modified precursor peptide 3.2
ProcA3.3-G−1K modified precursor peptide 1.7
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acid p-benzoyl-L-Phe (pBpa) at the site of the amber stop codon.12 The nonproteinogenic 
amino acid pBpa was added to the medium during the overexpression, and the resulting 
peptide containing pBpa was fully modified by ProcM. The photo-crosslinking group 
pBpa has been demonstrated as a useful probe for studying protein-protein13 and protein-
DNA interactions14 in cells. Upon incubation with producing and non-producing 
Prochlorococcus strains and UV irradiation at < 365 nm, pBpa-containing prochlorosins 
are expected to crosslink to biomolecules with which they interact. This Pcn3.2 analog 
with a photocrosslinking amino acid (Figure 2.5D) may provide a valuable tool for 
determination of prochlorosin biological activity.  
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Pcn3.2TEV_F26B     
NLYFQGGGCDGIRITDKQTVADNTIVPCSCBHQ 
Figure 2.11 MALDI-MS spectrum of ProcA3.2TEV with Phe26 substituted by pBpa, modified 
by ProcM in E. coli and treated with GluC to remove the major part of the leader peptide. The 
remaining residues of the leader peptides after GluC cleavage are highlighted in yellow in the 
amino acid sequence shown in the figure. “B” representing the incorporation of pBpa is 
highlighted in grey. Cysteine residues are highlighted in red. Serine and threonine residues are 
highlighted in green. After modification by ProcM, these serine and threonine residues were 
dehydrated, which caused a mass shift in the MALDI-MS compared with the calculated mass of 
unmodified peptide with the same sequence (denoted as M in the figure). A small amount of 
peptide resulting from translation termination at the amber stop codon is seen around 3100 Da. 
The ion with three dehydrations in the core peptide was the major product along with a minor 
amount of product with two dehydrations, as shown in the inset. 
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2.3 SUMMARY AND OUTLOOK 
        Prochlorosins are class II lanthipeptides produced by cyanobacteria of the genus 
Prochlorococcus. Prochlorococcus MIT9313 encodes one LanM-like synthetase ProcM 
and 29 LanA-like substrates ProcAs. ProcM was able to modify 16 wild-type ProcAs, 
with the 13 remaining ProcAs not investigated yet. Thus far, no biological activities have 
been observed with the prochlorosins. In the work described in Chapter 2, in vitro 
modification of two wild-type ProcAs and several ProcA mutants for proteolytic removal 
of the leader peptides were performed. Remarkably, a co-expression technique was 
successful in producing modified ProcAs in E. coli. Combined with in vitro proteolysis 
and reversed-phase purification, the in vivo co-expression method was able to produce 
procholorosins in sufficient quantity for downstream bioactivity assays to decipher the 
biological role of prochlorosins. The work described in this chapter also facilitated the 
interpretation of the stereochemistry of the lanthionine and methyllanthionine residues in 
several prochlorosins.15 
 
2.4 MATERIALS AND METHODS 
2.4.1 Materials 
        All oligonucleotides were purchased from Integrated DNA Technologies. 
Restriction endonucleases, DNA polymerases, and T4 DNA ligase were purchased from 
New England Biolabs or Invitrogen. Media components for bacterial cultures were 
purchased from Difco laboratories. Chemicals were purchased from Fisher Scientific or 
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from Aldrich unless noted otherwise. Endoproteinases Glu-C, Lys-C, Asp-N, and trypsin 
were purchased from Roche Biosciences or Worthington Biosciences. Factor Xa protease 
was purchased from New England Biolabs. Tobacco etch virus (TEV) protease was 
prepared as described previously.
16
 E. coli DH5α was used as host for cloning and 
plasmid propagation, and E. coli BL21 (DE3) was used as a host for co-expression. 
 
2.4.2 General methods 
        Negative residue numbers are used for amino acids in the leader peptide counting 
backwards from the leader peptide cleavage site, i.e. the residue immediately N-terminal 
to the cleavage site is −1. The plasmids, procA1.7-G−1R/pET15b, procA2.11/pET15b, 
procA3.2/pET15b, procA3.3/pET15b, and procM/pET28b that were used as templates for 
PCR were reported previously.
6
 All polymerase chain reactions (PCR) were carried out 
on a C1000™ thermal cycler (Bio-Rad). DNA sequencing was performed by the 
Biotechnology Center at the University of Illinois at Urbana-Champaign, using 
appropriate primers. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-ToF MS) was carried out on a Voyager-DE-STR (Applied 
Biosystems). Liquid chromatography electrospray ionization tandem mass spectrometry 
(LC/ESI-MS/MS) was carried out and processed using a Synapt ESI quadrupole ToF 
Mass Spectrometry System (Waters) equipped with an Acquity Ultra Performance Liquid 
Chromatography (UPLC) system (Waters). Solid-phase peptide synthesis was performed 
on a CEM Liberty microwave peptide synthesizer. 
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2.4.3 Construction of procA2.4/pET15b and procA2.8/pET15b 
The procA2.4 and procA2.8 genes were cloned into a pET15b vector between the 
NdeI and XhoI restriction sites using nested PCR with genomic DNA of Prochlorococcus 
MIT9313 (provided by Prof. Sallie Chisholm from the Massachusetts Institute of 
Technology) as the template (primer sequences are listed in Table 2.2). As the sequences 
at the 5’ end of procA2.1 - procA2.11 are very similar to each other, a primer (outside FP) 
annealing specifically to a DNA sequence upstream of the target gene was used in the 
first round PCR for both genes. For the more diverse 3’ ends, regular reverse primers 
were used. In the second round, a regular primer complementary to the exact 5’ end of 
ProcA was employed to amplify the target gene from the product of the first round PCR. 
The first round PCR amplification was performed by thirty cycles of denaturing (98 °C 
for 10 s), annealing (55.5 °C for 30 s) and extending (72 °C for 30 s). 
ProcA2.4_outside_FP and ProcA2.4_XhoI_RP were used to generate the larger gene 
sequence containing the entire sequence of procA2.4. In the second round PCR, 
ProcA2.4_NdeI_FP and ProcA2.4_XhoI_RP were used for generating the sequence 
encoding ProcA2.4, using the same PCR program as the first round. The PCR mixture 
included 1× Phusion HF buffer (New England BioLabs), dNTP mixture (0.2 mM each), 
primers (stock solution 100 M each, final concentration 2 M each), DMSO (4%, v/v), 
and Phusion High-Fidelity DNA Polymerase (0.02 U/L). Amplifications were confirmed 
by 1.5% agarose gel electrophoresis. The PCR products were purified by agarose gel 
electrophoresis followed by using a QIAquick Gel Extraction Kit (QIAGEN). The 
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resulting DNA fragments and pET15b vector were digested using NdeI and XhoI 
restriction enzymes in 1× NEBuffer 4 (New England BioLabs), incubated at 37 °C for 12 
h, followed by the addition of Calf Intestinal Alkaline Phosphatase (CIP, 200 U/mL, New 
England BioLabs) to remove the 5’ phosphate group from the digested vector, preventing 
the self-ligation of the cleaved vector. The digested products were purified by agarose gel 
electrophoresis followed by using QIAquick Gel Extraction Kit (QIAGEN). The resulting 
DNA inserts were ligated with the digested pET15b vector using T4 DNA ligase 
(Invitrogen) in ligase buffer. The mixture was incubated at 24 °C for 30 min, followed by 
23 °C for 3 h. The ligation mixture was diluted 5 times with water before E. coli DH5α 
cells were transformed with the ligation product via heat shock and plated onto LB-
Ampicillin agar plates, followed by incubating the plates at 37 °C overnight. Several 
colonies on the plates were picked and individually incubated in 5 mL of LB medium at 
37 °C overnight. The plasmids were isolated using QIAprep Spin Miniprep Kit 
(QIAGEN). The correct sequences of the resulting plasmids were confirmed by DNA 
sequencing. The plasmid procA2.8/pET15b was generated the same way from 
Prochlorococcus MIT9313 genomic DNA. (Y.S. Notebook 3, Page 28 – 30). 
 
2.4.4 Mutagenesis of ProcA2.1, ProcA2.11 and ProcA3.2 
Mutagenesis of procA2.1, procA2.11 and procA3.2 to install a cleavage site for a 
commercial protease to remove the leader sequence was performed by Megaprimer PCR 
(for primer sequences see Table 2.2). In the first round PCR, ProcA2.1_NdeI_FP and 
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ProcA2.1_Xa_for_FP were used for generating a megaprimer, which covered the 5’ end 
of procA2.1 and sequences encoding IEGR as the 3’ end of the product, for subsequent 
rounds. Meanwhile, ProcA2.1_XhoI_RP and ProcA2.1_Xa_for_RP were used for 
generation of a megaprimer covering the 3’ end of procA2.1 and encoding IEGR as the 5’ 
end of the megaprimer. The resulting products from the two separate PCR reactions were 
purified by agarose gel electrophoresis followed by using a QIAquick Gel Extraction Kit 
(QIAGEN). In this first round, the PCR amplification was performed by thirty cycles of 
denaturing (98 °C for 10 s), annealing (55 °C for 30 s) and extending (72 °C for 15 s). 
Wild type procA2.1/pET15b was used as the template for the first round PCR, while the 
annealed and amplified megaprimer products were used for the second round PCR. The 
same PCR conditions were repeated for seven cycles in the second round PCR 
amplifications. After the first seven cycles, ProcA2.1_NdeI_FP and ProcA2.1_XhoI_RP 
were added to the reaction, followed by twenty-two cycles under the same PCR 
conditions to generate sequences containing appropriate mutations. The PCR mixture 
included 1× Phusion HF buffer (New England BioLabs), dNTP mixture (0.2 mM each), 
primers (1 M each), DMSO (4%, v/v), and Phusion High-Fidelity DNA Polymerase 
(0.02 U/L). Amplifications were confirmed by 1.5% agarose gel electrophoresis. The 
product was purified by agarose gel electrophoresis followed by using a QIAquick Gel 
Extraction Kit (QIAGEN), and inserted into a pET15b vector after digestion, ligation and 
transformation as described before. The desired mutations were confirmed by DNA 
sequencing. In the case of ProcA2.1, residues AAGG were replaced by IEGR to produce 
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ProcA2.1Xa, while residues SVAGG were replaced by ENLYFQ to afford 
ProcA2.11TEV. Plasmids encoding ProcA2.11Xa, ProcA2.11TEV, ProcA3.2Xa, and 
ProcA3.2TEV were constructed the same way as described here by replacing certain 
residues using IEGR or ENLYFQ. All mutations were verified by DNA sequencing. (Y.S. 
Notebook 2, Page 74 – 75, 78 – 81, 82 – 93; Notebook 3, Page 15 – 19).  
 
2.4.5 Overexpression and purification of linear precursor peptides of ProcA and 
ProcA mutants 
E. coli BL21 (DE3) cells transformed with a procA/pET15b vector constructed as 
Primer Name Primer Sequence (5'-3')
procA2.1 NdeI_FP GCA ATC CAC ATA TGT CAG AAG AAC AAC TCA AAG C
procA2.1 XhoI_RP ATA CAA TCC TCG AGT CAG TAG CAG CCT CCT G
ProcA2.1_Xa_FP GAG GAG CTG GAG GGC ATT GAA GGA CGT TGC TGC ATC ACC GGG 
ProcA2.1_Xa_RP CCC GGT GAT GCA GCA ACG TCC TTC AAT GCC CTC CAG CTC CTC 
procA2.11 NdeI_FP GCA ATC CAC ATA TGT CAG AAG AAC AAC TCA AAG C
procA2.11 XhoI_RP ATA CAA TCC TCG AGC TAG CAA CAG GTA CCG GTC
ProcA2.11_Xa_FP GAT GAG CTT GAA AGT ATT GAA GGG CGT GGG AGG ATT GAT ACC 
ProcA2.11_Xa_RP GGT ATC AAT CCT CCC ACG CCC TTC AAT ACT TTC AAG CTC ATC 
ProcA2.11_TEV_FP GAG GAT GAG CTT GAA AAT CTG TAT TTC CAA GGG AGG ATT GAT ACC 
ProcA2.11_TEV_RP GGT ATC AAT CCT CCC TTG GAA ATA CAG ATT TTC AAG CTC ATC CTC 
procA3.2 NdeI_FP GCA ACC TAC ATA TGT CAG AAG AAC AAC TCA AGG C
procA3.2 XhoI_RP ATA CAA TCC TCG AGT CAC TGG TGG AAG CAG
ProcA3.2_Xa_FP GAT GAG CTG GAA GGT ATT GAA GGG CGT GGG GGA GGC TGT GAC 
ProcA3.2_Xa_RP GTC ACA GCC TCC CCC ACG CCC TTC AAT ACC TTC CAG CTC ATC 
ProcA3.2_TEV_FP GAT GAT GAG CTG GAA AAT TTG TAT TTT CAA GGG GGA GGC TGT GAC 
ProcA3.2_TEV_RP GTC ACA GCC TCC CCC TTG AAA ATA CAA ATT TTC CAG CTC ATC ATC 
ProcA2.4_outside_FP GCT GGC AGC TGT AAC TGG ATA TGC 
ProcA2.4_NdeI_FP GTA AGT ACC ATA TGA GCG AAG AAC AAC TCA AGG C 
ProcA2.4_XhoI_RP AAT CAT AAC TCG AGC TAA TGG CTC AAC CAA CAC 
ProcA2.8_outside_FP GTT ATC CGA TCT GTG ACT GGA CGT CG 
ProcA2.8_NdeI_FP GTA AGT ACC ATA TGT CAG AAG AGC AAC TGA AGG C 
ProcA2.8_XhoI_RP TTA CAA TCC TCG AGT TAG CAC TCA CCC TCC 
Table 2.2 Primer sequences for cloning and mutagenesis of procAs in pET15b. 
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described in section 2.4.3 and 2.4.4 were grown in 2 L of LB medium containing 100 
mg/L ampicillin at 37 °C until the O.D.600 nm reached about 0.8. The culture was then 
induced with 1.0 mM isopropyl β–D–1-thiogalactopyranoside (IPTG) and shaken 
continually at 37 °C for an additional 3 h. The induced cells were harvested by 
centrifugation (11,900 × g for 20 min at 4 °C, Beckman JLA-10.500 rotor). The cell 
pellet was resuspended in 20 mL of LanA Start Buffer (20 mM NaH2PO4, pH 7.5 at 
25 °C, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol) and lysed by sonication (35% 
amplitude, 4.0 s pulse, 9.9 s pause, 15 min). The sample was centrifuged (23,700 × g for 
40 min at 4 °C) and the pellet was resuspended in 20 mL of LanA Start Buffer again to 
remove possibly remaining soluble proteins in the pellet. After centrifugation again, the 
cell pellet was resuspended in 20 mL of LanA Buffer 1 (6 M guanidine hydrochloride, 20 
mM NaH2PO4, pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole). The soluble portion 
after centrifugation (23,700 × g for 20 min at 4 °C), which contained His6-tagged ProcAs, 
was clarified using 0.45 μm syringe filters (Corning), then purified by immobilized metal 
affinity chromatography (IMAC) using a 5 mL HisTrap HP nickel affinity column (GE 
Healthcare Life Sciences). The filtered sample was applied to the column and the column 
was washed with 2 column volumes (CV) of LanA Buffer 1, followed by 2 - 3 CV of 
LanA Buffer 2 (4 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 300 
mM NaCl, 30 mM imidazole), and then eluted with 3 CV of LanA Elution Buffer (4 M 
guanidine hydrochloride, 20 mM Tris, pH 7.5 at 25 °C, 100 mM NaCl, 1 M imidazole). 
The elution fractions were immediately used or stored at room temperature overnight and 
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then desalted and purified by preparative reversed-phase high-performance liquid 
chromatography (RP-HPLC) using a Waters Delta-pakTM C4; 15 m; 300 Å; 25 × 100 
mm PrepPac® Cartridge. Solvents for the RP-HPLC were solvent A (0.1% TFA in water) 
and solvent B (0.086% TFA in 80% acetonitrile / 20% water). A gradient of 2-100% of 
solvent B was executed over 45 min at a flow rate of 8 mL/min, while peptides were 
detected by absorbance at 220 nm. The fractions were tested by MALDI-ToF-MS for the 
desired peptides. All the fractions containing the desired pure product were combined and 
the organic solvents were removed by rotary-evaporation, followed by lyophilization 
overnight. The product was kept at –20 °C for short-term storage and –80 °C for long-
term storage. The yields of the peptides were 25.5 mg, 37.1 mg, 145.3 mg, 38 mg, 11.9 
mg, 6.7 mg, and 33.2 mg for His6-ProcA2.4, His6-ProcA2.8, His6-ProcA 2.1Xa, His6-
ProcA2.11Xa, His6-ProcA2.11TEV, His6-ProcA3.2Xa, and His6-ProcA3.2TEV from 4 L 
cell culture, respectively. (Y.S. Notebook 2, Page 94 – 99; Notebook 3, Page3 – 9, 32 – 
33, 36 – 38). 
 
2.4.6 Overexpression and purification of His6-tagged ProcM 
E. coli BL21 (DE3) cells were transformed with procM/pET28b via electroporation. 
The cells were grown in 2 L of LB medium containing 50 mg/L kanamycin at 37 °C until 
the O.D.600 nm reached about 0.6. Then the incubation temperature was reduced to 18 °C 
and the culture was induced with 0.1 mM IPTG and shaken aerobically continuously for 
an additional 20 h. The cells were harvested by centrifugation (5000 × g for 20 min at 
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4 °C). The cell pellet was resuspended in 20 mL of ProcM Start Buffer (20 mM Tris, pH 
8.0 at 4 °C, 1 M NaCl, 10% glycerol) and was disrupted by multiple passes through an 
Avestin C5 Emulsiflex Homogenizer. The insoluble aggregates and cellular debris were 
then discarded after centrifugation (23,700 × g for 30 min at 4 °C). The supernatant was 
passed through 0.45 μm syringe filters (Corning), followed by nickel affinity fast protein 
liquid chromatography purification (FPLC) using an Amersham Biosciences/GE 
Healthcare ÄKTA system. A 5 mL HisTrap HP nickel affinity column (GE Healthcare 
Life Sciences) was connected to the FPLC system for the purification at 4 °C. Solvents 
for FPLC were solvent A (ProcM Start Buffer) and solvent B (ProcM Elution Buffer: 20 
mM Tris, pH 8.0 at 4 °C, 1 M NaCl, 200 mM imidazole). A gradient of 0 - 100% of 
solvent B over 45 min was executed with a flow rate of 2 mL/min. Proteins were detected 
by absorbance at 280 nm and collected in 4 mL fractions. The fractions were analyzed for 
purity by Tris-Glycine SDS-PAGE (4 - 20% acrylamide gradient). All the fractions 
containing the pure desired protein were combined and concentrated using an Amicon 
Ultra-15 Centrifugal Filter Unit (30 kDa MW cut off for His6-ProcM) to about 2.5 mL. 
Then the buffer of the concentrated protein was exchanged to ProcM Start Buffer using a 
PD-10 desalting column (GE Healthcare Life Sciences). The concentration of the protein 
was determined by absorbance at 280 nm, demonstrating protein yields of 8.5 mg for 
His6-ProcM from 2 L overexpression culture. The resulting protein sample was stored at 
–80 °C with the addition of 10% (v/v, final concentration) glycerol. (Y.S. Notebook 3, 
Page 16 – 20). 
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2.4.7 Activity assays for ProcM 
Activity assays for ProcM with ProcA peptides and ProcA mutants were carried out 
in a solution containing 50 mM HEPES (pH 7.5), 2.5 mM ATP, 0.5 mM tris(2-
carboxyethyl)phosphine (TCEP), and 10 mM MgCl2. The final concentrations of ProcA 
peptides and ProcM were estimated to be 75 μM and 9.8 μM, respectively. The reaction 
mixture was incubated at room temperature overnight (15 - 20 h) unless noted otherwise. 
The products were analyzed by MALDI-ToF MS. (Y.S. Notebook 3, Page 10 – 15, 21 – 
23, 39, 49). 
 
2.4.8 Construction of pRSFDuet-1 derivatives for co-expression of ProcM and 
ProcA 
        The procM gene was cloned by PCR from procM/pET28b (see reference6) and 
inserted into multiple cloning site-2 (MCS2) of the pRSFDuet-1 vector between the NdeI 
and KpnI restriction sites (for all primer sequences, see Table 2.3). The procA1.4-G−1E, 
1.6-G−1R, 1.7-G−1E, 2.1-G−1R/G−1E, 2.8-G−1K, 2.11-G−1K, 3.2TEV, 3.3-G−1K, 
4.1TEV, 4.3-G−1R/G-1E, 4.4-G−1E, and s.1-G−1K genes were generated using overlap 
extension PCR with the originally reported pET15b expression plasmids6 as templates, 
while procA2.8-G−1K-His6 (encoding ProcA2.8 with C-terminal His6-tag instead of N-
terminal) and 3.3-G−1K -His6 were also generated using overlap extension PCR but 
using the previously generated procA2.8-G−1K/procM/pRSFDuet-1 and  procA3.3-
G−1K/procM/pRSFDuet-1 as the templates, respectively (Y.S. Notebook 4, Page 52-55, 
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59, and 93 – 96. Caitlin’s Rotation-Notebook 1 – 14, 16 – 19. Manuel’s Rotation-
Notebook 18 – 39). The procA1.2A−1K, 1.3G−1K, 1.5A−1K, 1.6, 1.7G−1R and 
3.3G−1E genes were cloned by regular PCR (Y.S.    Notebook 4 Page 23, 52 – 55, 59, 93 
– 96. Caitlin’s Rotation-Notebook 1 – 14, 16 – 19.   Manuel’s Rotation-Notebook 18 – 
39), because the mutant constructs already existed in pET15b vectors that were 
constructed by Dr. Li. In the case of ProcA3.2, the residues GVAGG at the C-terminus of 
the leader peptide were replaced with NLYFQ, generating the ENLYFQ cleavage site 
recognized by TEV protease. Except procA2.8-G−1K-His6 and procA3.3-G−1K-His6, 
which were each cloned into the pRSFDuet-1 vector between NcoI and NotI restriction 
sites (Y.S. Notebook 7 Page 6), the mutant procA genes were individually cloned into 
MCS1 of the pRSFDuet-1 vector between the EcoRI and NotI restriction sites, all with 
the procM gene inserted in MCS2. The sequences of the resulting plasmids were 
confirmed by DNA sequencing. The amino acid sequences of ProcA1.7-G−1R, 
ProcA2.11-G−1K, ProcA3.2TEV and ProcA3.3-G−1K are shown in Figure 2.12. 
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Table 2.3 Primer sequences for cloning and mutagenesis of procAs for co-expression. 
Primer Name Primer Sequence (5'-3')
ProcA1.2_EcoR I_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTG 
ProcA1.2_Not I_RP_Duet TAA ATT ATG CGG CCG CTC ACC GTA AGT C 
ProcA1.3_EcoR I_FP_Duet GGT TAG TGG AAT TCG ATG TCA GAA GAA CAA CTC 
ProcA1.3_Not I_RP_Duet TAA ATT ATG CGG CCG CTT ACT CTG AGG T 
ProcA1.4_EcoR I_FP_Duet CGG TGA GTG GAA TTC GAT GTC AGA AGA ACA ACT GAA GGC 
ProcA1.4_Not I_RP_Duet GTA TAA ATA AGC GGC CGC CTA GCT CGG ACA GGC AG
ProcA1.4_G−1E_FP GAA GGT GTG GCT GGG GAA GGA AGC TCG TAC AGA AAC
ProcA1.4_G−1E_RP GTT TCT GTA CGA GCT TCC TTC CCC AGC CAC ACC TTC
ProcA1.4_G−1K_FP GAA GGT GTG GCT GGG AAA GGA AGC TCG TAC AGA AAC
ProcA1.4_G−1K_RP GTT TCT GTA CGA GCT TCC TTT CCC AGC CAC ACC TTC
ProcA1.5_EcoR I_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTC
ProcA1.5_Not I_RP_Duet TAA ATT ATG CGG CCG CTC ATC CCT CAC 
ProcA1.6_EcoR I_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTC AAG
ProcA1.6_Not I_RP_Duet AAT AAA TAT GCG GCC GCT CAC AGC CAA CAC 
ProcA1.6_G−1R_FP GAA GGT GTA GCT GGC CGC AAA TCT ACT AAT GGA TG
ProcA1.6_G−1R_RP CAT CCA TTA GTA GAT TTG CGG CCA GCT ACA CCT TC
ProcA1.7_EcoR I_FP_Duet GGT GCG AGG AAT TCG ATG AAG CAT AGA CAA CTA AAT CTG
ProcA1.7_Not I_RP_Duet ATA ATA TCG CGG CCG CTC AGC ACA TTT TCC C
ProcA1.7_G−1E_FP GTG TGG CTG GGG AAA CCA TTG GGG GAA C
ProcA1.7_G−1E_RP GTT CCC CCA ATG GTT TCC CCA GCC ACA C
ProcA2.1_EcoR I_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTC AAA GC 
ProcA2.1_Not I_RP_Duet ATA ATT TAG CGG CCG CTC AGT AGC AGC CTC 
ProcA2.1_G−1R_FP GCA GCC GGA CGC TGC TGC ATC 
ProcA2.1_G−1R_RP GAT GCA GCA GCG TCC GGC TGC 
ProcA2.1_G−1E_FP CGC AGC CGG AGA GTG CTG CAT CAC 
ProcA2.1_G−1E_RP GTG ATG CAG CAC TCT CCG GCT GCG 
ProcA2.8_EcoR I_FP_Duet GCA ACC TAG AAT TCG ATG TCA GAA GAG CAA CTG AAG G
ProcA2.8_Not I_RP_Duet ATA TAA TGC GGC CGC TTA GCA CTC ACC CTC
ProcA2.8_G−1K_FP GTG GCT GGG AAA GCG GCC TGT CAT AAC 
ProcA2.8_G−1K_RP GTT ATG ACA GGC CGC TTT CCC AGC CAC
ProcA2.11_EcoR I_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTC AAA GC 
ProcA2.11_Not I_RP_Duet ATA ATT TAG CGG CCG CCT AGC AAC AGG TAC C
ProcA2.11_G−1K_FP GAA AGT GTG GCT GGC AAA GGG AGG ATT GAT ACC 
ProcA2.11_G−1K_RP GGT ATC AAT CCT CCC TTT GCC AGC CAC ACT TTC
ProcA3.2_EcoR I_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTC AAG GC 
ProcA3.2_Not I_RP_Duet ATA ATT TAG CGG CCG CTC ACT GGT GGA AGC
ProcA3.2_TEV_FP GAT GAT GAG CTG GAA AAT TTG TAT TTT CAA GGG GGA GGC TGT GAC 
ProcA3.2_TEV_RP GTC ACA GCC TCC CCC TTG AAA ATA CAA ATT TTC CAG CTC ATC ATC 
ProcA3.3_EcoR I_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTC AAG GC 
ProcA3.3_Not I_RP_Duet ATA ATT TAG CGG CCG CCT ATG CGC GGC
ProcA3.3_G−1K_FP CCG CTA GCG GCA AAG GCG ATA CCG 
ProcA3.3_G−1K_RP CGG TAT CGC CTT TGC CGC TAG CGG
ProcA4.1_EcoR I_FP_Duet GGT GGG TGG AAT TCG ATG TCA GAA GAG CAA CTC 
ProcA4.1_Not I_RP_Duet CAT AGG ATG CGG CCG CTT AGG TTT GGT TTT C 
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2.4.9 Overexpression and purification of His6-tagged modified ProcA and ProcA 
mutants 
        E. coli BL21 (DE3) cells transformed with a pRSFDuet-1 vector carrying the genes 
for one of the ProcA peptides as well as procM were grown in 2 L of LB medium 
containing 50 mg/L kanamycin at 37 °C until the O.D.600 nm reached 0.6 - 0.8. The culture 
was then induced with 0.1 mM isopropyl β–D–1-thiogalactopyranoside (IPTG) and 
Table 2.3 (cont.) 
Primer Name Primer Sequence (5'-3')
ProcA4.1_TEV_FP AAG TGA GCT GGA AAA TCT GTA TTT TCA AGG GGG GGG AG 
ProcA4.1_TEV_RP CTC CCC CCC CTT GAA AAT ACA GAT TTT CCA GCT CAC TT 
ProcA4.3_EcoR I_FP_Duet GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTG AAG GC
ProcA4.3_Not I_RP_Duet ATG ACC TAG CGG CCG CCT AGT AAC AAA ACA TAC
ProcA4.3_G−1R_FP GTG TGG CTG GGC GCA CTG CAT CTG
ProcA4.3_G−1R_RP CAG ATG CAG TGC GCC CAG CCA CAC
ProcA4.3_G−1E_FP GTG TGG CTG GGG AAA CTG CAT CTG GTG
ProcA4.3_G−1E_RP CAC CAG ATG CAG TTT CCC CAG CCA CAC
ProcA4.4_EcoR I_FP_Duet CTC GAG GGT GAG TGG AAT TCG ATG CAT TCA TCA GCC
ProcA4.4_Not I_RP_Duet GCA GAC GTA TGC GGC CGC TCA ACA ATA TTT GCT G
ProcA4.4_G−1E_FP GAA AGC GCG GCT GGT GAA AGG CTC AAG AGT GGA TG
ProcA4.4_G−1E_RP CAT CCA CTC TTG AGC CTT TCA CCA GCC GCG CTT TC
ProcAs.1_EcoR 1_FP_Duet GGT GAG TGG AAT TCG ATG CTG CTT GCA GAA GAG ACA ATT G
ProcAs.1_Not 1_RP_Duet GCA TAA GTT TGC GGC CGC TTA TCC ATG ACT CGG ATA ATG
ProcAs.1_G−1K_FP GAA AGC GTC GCT GGC AAA GCC CAA TCG G
ProcAs.1_G−1K_RP CCG ATT GGG CTT TGC CAG CGA CGC TTT C
ProcA2.8_Nco I_FP
a
GAT AAG TGC CAT GGG CAT GTC AGA AGA GCA ACT GAA GGC 
ProcA2.8_His6_Not I_RP
a
ATA TAA TGC GGC CGC TCA ATG ATG ATG ATG ATG ATG GCA CTC ACC CTC
ProcA3.3_Nco I_FP
b
GAT AAG TGC CAT GGG CAT GTC AGA AGA ACA ACT CAA GGC 
ProcA3.3_His6_Not I_RP
b
ATA TAA TGC GGC CGC TCA ATG ATG ATG ATG ATG ATG TGC GCG GCA CAT TTT G
ProcM_Nde I_FP_Duet GGT TGG TTC ATA TGG AAA GTC CAT CAT CTT GG
ProcM_Kpn I_RP_Duet GTC TCT GGC CTA CTG AAT AAG GTA CCA ATC ATC T 
a: Primers used for generating procA2.8-G−1K-His6 
b: Primers used for generating procA3.3-G−1K-His6 
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shaken continually at 18 °C for an additional 20 h. The induced cells were harvested by 
centrifugation (11,900 × g for 20 min at 4 °C). The cell pellet was resuspended in 20 mL 
of LanA Start Buffer (20 mM NaH2PO4, pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM 
imidazole, 20% glycerol) and lysed by sonication (35% amplitude, 4.0 s pulse, 9.9 s 
pause, 15 min). The sample was centrifuged (23,700 × g for 40 min at 4 °C) and the 
supernatant was kept for further purification. The pellet was resuspended in 20 mL of 
LanA Start Buffer to obtain all the soluble proteins remaining in the pellet. Insoluble 
materials were removed from the combined soluble fractions by centrifugation (23,700 × 
g for 20 min at 4 °C), and the resulting sample was clarified using a 0.45 μm syringe 
filter (Corning). The His6-tagged peptides were then purified by immobilized metal 
affinity chromatography (IMAC) using a 5 mL HisTrap™ HP nickel affinity column (GE 
Healthcare Life Sciences). The filtered sample was applied to the column and the column 
was washed with 2 column volumes of LanA Buffer 1 (6 M guanidine hydrochloride, 20 
mM NaH2PO4, pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole), followed by 2 - 3 
column volumes of LanA Buffer 2 (4 M guanidine hydrochloride, 20 mM NaH2PO4, pH 
7.5 at 25 °C, 300 mM NaCl, 30 mM imidazole), and then eluted with 3 column volumes 
of LanA Elution Buffer (4 M guanidine hydrochloride, 20 mM Tris, pH 7.5 at 25 °C, 100 
mM NaCl, 1 M imidazole).  
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        The elution fractions were purified by preparative reversed-phase high-performance 
liquid chromatography (RP-HPLC) using a Waters Delta-pak™ C4 (15 µm; 300 Å; 25 × 
100 mm PrepPac® Cartridge) column. Solvents for RP-HPLC were solvent A (0.1% TFA 
in water) and solvent B (0.086% TFA in 80% acetonitrile / 20% water). A gradient of 2 - 
Figure 2.12 Precursor peptide sequences of some of the lanthipeptides used in this study. 
The leader peptides are highlighted in yellow. Black arrows indicate the cleavage sites. 
Mutated amino acids introduced for commercial protease cleavage are in bold font and 
underlined. Cysteine residues in the core peptides are highlighted in red. Serine and 
threonine residues in the core peptides are highlighted in green. Red lines indicate the rings 
formed after ProcM modification.6 Purple lines indicate putative ring topology after ProcM 
modification. Tandem mass spectrometry has confirmed the existence of overlapping rings 
at the C-terminal core peptide regions of Pcn2.11 and Pcn3.2 obtained both in vivo (Figure 
2.6) and in vitro.6 However, how the two rings overlap is currently not known and one 
possible ring topology is shown. 
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100% of solvent B was executed over 45 min at a flow rate of 8 mL/min, and peptides 
were detected by absorbance at 220 nm. The fractions were analyzed by MALDI-ToF-
MS. All the fractions containing the desired product were combined and the organic 
solvents were removed by rotary evaporation, followed by lyophilization overnight. The 
product was kept at −20 °C for short-term storage and −80 °C for long-term storage. The 
yields of the peptides were 22.6 mg, 62.0 mg, 57.9 mg, and 61.7 mg, respectively, for 
modified His6-ProcA1.7-G−1R, His6-ProcA2.11-G−1K, His6-ProcA3.2TEV, and His6-
ProcA3.3-G−1K from 2 L of cell culture. Modified His6- ProcA1.2-A−1K, 1.3-G−1K, 
1.4G-1E, 1.5-A−1K, 1.6, 1.6-G−1R, 1.7-G−1E, 2.1-G−1R/G−1E, 2.8-G−1K, 3.3-G−1E, 
4.1TEV, 4.3-G−1R/G−1E, 4.4-G−1E, s.1-G−1K, 2.8-G−1K-His6 and 3.3-G−1K-His6 
were also overexpressed and purified in the same way. (Y.S. Notebook 4 Page 24 – 28, 60 
– 68, 85, 91 – 92, 97 – 98, Notebook 5 Page 8 – 9, 11 – 12, 27, 34, Notebook 7 Page 16 – 
17, Notebook 9 Page 32 – 33. Caitlin’s Rotation-Notebook Page 13 and 15. Manuel’s 
Rotation-Notebook Page 8 – 16). 
 
2.4.10 Protease cleavage 
        Modified ProcA mutants from either in vivo co-expression or in vitro enzymatic 
assay were cleaved by a commercial protease (trypsin for ProcA1.6-G−1R, ProcA1.7-
G−1R, and 4.3-G−1R, Lys-C for ProcA1.2-A−1K, 1.3-G−1K, 1.5-A−1K, 2.8-G−1K, 
2.11-G−1K, 3.3-G−1K, s.1-G−1K, 2.8-G−1K-His6, and 3.3-G−1K-His6, Glu-C for 
ProcA1.6, 2.8, and 4.4-G−1E, Asp-N for ProcA2.4 and 2.8, TEV protease for 
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ProcA2.11TEV, 3.2TEV, and 4.1TEV, and Factor Xa for ProcA2.1Xa, 2.11Xa, and 
3.2Xa) to remove the leader peptide. Linear ProcA3.2TEV was also cleaved by TEV 
protease to generate linear un-modified ProcA3.2 core peptide. MALDI-TOF mass 
spectra of some of the modified peptides treated by proteases are shown in Figure 2.5. 
(Y.S. Notebook 4 Page 29, 42, 50 – 51, 62, 68 – 70, and 99 – 100, Notebook 5 Page 18, 
Notebook 9 Page 28 – 32, 35). 
 
2.4.11 Tandem mass spectrometry analysis of prochlorosins and their derivatives 
        The ring topology of lanthipeptides was deduced from their MS fragmentation 
pattern. A sample of 10 μL of in vitro ProcM dehydration assay after protease cleavage, 
or a sample of 5 μL of each protease cleavage reaction mixture starting from in vivo co-
expression products was injected to a BEH C8 column (1.7 μm, 1.0 × 100 mm), and the 
fully modified product was purified by UPLC using a gradient of 3% mobile phase B 
(0.1% formic acid in methanol) to 97% mobile phase B in mobile phase A (0.1% formic 
acid in water) over 12 min. Mass spectra were acquired in ESI positive mode in the range 
of 50-2000 m/z. The capillary voltage was 3500 V, and the cone voltage was 40 V. The 
other parameters used were as follows: 120 °C source temperature; 300 °C desolvation 
temperature, 150 L/h cone gas flow, and 600 L/h desolvation gas flow. A transfer 
collision energy of 4 V was used for both MS and tandem MS, while the trap collision 
energy was set to 6 V for MS and a 20−55 V ramp for MSMS depending on the peptide. 
Glu-fibrinopeptide B (Sigma) was directly infused as the lock mass. The tandem mass 
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spectra were processed with MaxEnt3 and analyzed by Protein/Peptide Editor in BioLynx 
4.1. The software for analyzing both precursor-ions and fragment-ions was set to report 
any mass within 0.3 amu of the calculated expected values. Tandem mass spectra of the 
fully modified peptides treated by proteases (ProcA1.7-G−1R core peptide with five 
dehydrations, ProcA2.11-G−1K core peptide with five dehydrations, ProcA3.2TEV core 
peptide with three dehydrations, and ProcA3.3-G−1K core peptide with three 
dehydrations) are shown in Figure 2.6. Fragmentation patterns of these core peptides 
were consistent with the ring topology of prochlorosins previously obtained in vivo and in 
vitro.6 Therefore, they are denoted as “Pcn in E. coli” (Pcn is short for prochlorosin, i.e. 
prochlorosin 1.7 is denoted as Pcn1.7). (Y.S. Notebook 4 Page 37 – 38, 42 – 43, 47 – 49, 
81 – 82, Notebook 5 Page 15 – 17, 19, Notebook 9 Page 29, 34, 36 – 38). 
 
2.4.12 HPLC purification of prochlorosins modified in E. coli 
        The protease cleavage reactions were quenched with 0.5% TFA, and the desired 
products purified by analytical RP-HPLC using a Vydac™ C18 column (5 µm; 300 Å; 
4.6 i.d. × 250 mm). Solvents for RP-HPLC were solvent A (0.1% TFA in water) and 
solvent B (0.086% TFA in 80% acetonitrile / 20% water). A gradient of 0.8-100% of 
solvent B was executed over 50 min at a flow rate of 1 mL/min, and peptides were 
detected by absorbance at 220 nm. The fractions were tested by MALDI-ToF-MS for the 
desired peptides. All the fractions containing the desired fully modified product were 
combined and the solvents were removed by lyophilization overnight. The product was 
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kept at −20 °C for short-term storage and −80 °C for long-term storage. MALDI spectra 
of these purified prochlorosins are shown in Figure 2.9. (Y.S. Notebook 4 Page 34 – 36, 
56 – 58, 75 – 78, 83 – 85, and 86 – 90). 
 
2.4.13 Solid phase peptide synthesis (SPPS) of linear ProcA2.11 and ProcA3.2 core 
peptide derivatives 
Linear ProcA2.11 and ProcA3.2 core peptides, with all the cysteine residues 
substituted by serine residues, were synthesized on a 0.1 mmol scale using standard Fmoc 
solid phase peptide synthesis chemistry. As the starting material, 0.1 mmol Wang-resin 
preloaded with the C-terminal residue was swollen in 10 mL of 1:1 DCM:DMF. Fmoc-
amino acids were used at a scale of 0.2 M in 2.5 mL DMF for each coupling step. The 
coupling was performed with HCTU (0.5 M in DMF, 1 mL) as the coupling reagent and 
DIEA (2.0 M in 1-methyl-2-pyrrolidinone, 0.5 mL) as the activating reagent with 
microwave irradiation (3 min, 20 W, 75 °C). The Fmoc deprotection was performed in 
DMF containing 20% (v/v) piperidine assisted by microwave irradiation (3 min, 30 W, 
75 °C). (Y.S. Notebook 7, Page 85 – 86). 
 
2.4.14 Deprotection of solid phase synthesized products 
For a 0.1 mmol scale peptide synthesis, 4.6 mL TFA, 0.125 mL of water, 0.125 mL 
of TIPS, and 0.125 mL of thioanisole were added to the dried resin-bound peptide. The 
mixture was blanketed with nitrogen and stirred vigorously at room temperature for 2 h, 
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followed by passing through a coarse-grain Büchner funnel. The flow through was 
collected and the TFA was evaporated with a stream of nitrogen until only about 1 mL of 
solution was left, followed by the addition of cold diethyl ether. The peptide was 
precipitated and pelleted from the solution by centrifugation (6,000 rpm in a GA-10 rotor 
using a Beckman GS-6R centrifuge for 10 min at room temperature). The pellet was then 
dried under a nitrogen stream and redissolved in 3 mL of 1:1 (v/v) MeCN/H2O. Then, 2 
μL of the solution was used for analysis by MALDI-ToF MS. The remaining solution was 
frozen and lyophilized overnight. (Y.S. Notebook 7, Page  87). 
 
2.4.15 Purification of deprotected SPPS products 
The crude lyophilized product was redissolved in a minimal amount of 1:1 (v/v) 
MeCN/H2O and purified by preparative reversed-phase high-performance liquid 
chromatography (RP-HPLC) using a Waters Delta-pakTM C18 column (2.5 cm × 10.0 
cm). Solvents were solvent A (0.1% TFA in water) and solvent B (0.086% TFA in 80% 
acetonitrile / 20% water). A gradient of 2-100% of solvent B was executed over 45 min at 
a flow rate of 8 mL/min, and peptides were detected by absorbance at 220 nm. The 
fractions were analyzed by MALDI-ToF-MS for the desired peptides and all the fractions 
containing the desired pure product were combined and concentrated by rotary-
evaporation to remove acetonitrile and TFA, followed by lyophilization overnight. The 
product was kept at –20 °C for short-term storage and –80 °C for long-term storage. (Y.S. 
Notebook 7, Page 88). 
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2.4.16 Incorporation of para-benzoyl phenylalanine (pBpa or B) in ProcA3.2 
        The nucleotides encoding phenylalanine at position 26 of the gene for ProcA3.2TEV 
were substituted by the amber codon TAG. The mutant was generated by nested PCR 
using primers 5'- GCA GAC AAT ACA ATT GTC CCT TGC AGC TGC TAG CAC CAG 
TG -3' (3.2_F26B_FP) and 5'- ATA ATT TAG CGG CCG CTC ACT GGT GCT AGC AG 
-3' (3.2_F26B_RP). The vector procA3.2TEV/procM/pRSFDuet-1 was used as the 
template. (Y.S. Notebook 5 Page 31 – 33 and 35). 
        E. coli BL21 (DE3) cells were transformed with a pDule-Tyr vector (obtained from 
Professor Peter Schultz, the Scripps Research Institute. Basic information about the 
vector: it encodes pBpaRS and tRNACUA, tetracycline resistant, has a p15A origin of 
replication, and uses the constitutive lpp promoter) and a pRSFDuet-1 vector, carrying 
both procA3.2TEV_F26B and procM. The cells were grown in 400 mL of glycerol 
minimal medium, supplemented with metals, containing 50 mg/L kanamycin, 12.5 mg/L 
tetracycline and an 18-amino-acid solution (for components, see Reference 17 and 18). The 
pDule-Tyr vector carrying an orthogonal aminoacyl tRNA synthetase-tRNACUA pair can 
incorporate p-benzoyl-L-phenylalanine (pBpa) at the position encoded by the amber 
codon TAG. The culture was shaken at 37 °C until the O.D.600 nm reached 0.5, then pBpa 
dissolved in 1 M NaOH solution was added to the culture to obtain a final concentration 
of 1 mM pBpa. After shaking for 0.5 h, the culture was induced with 0.1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) and shaken continually at 18 °C for an additional 20 h. 
The induced cells were harvested by centrifugation (11,900 × g for 20 min at 4 °C). The 
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cell pellet was resuspended in 10 mL of LanA Start Buffer and lysed by sonication (35% 
amplitude, 4.0 s pulse, 9.9 s pause, 15 min). The sample was centrifuged (23,700 × g for 
40 min at 4 °C) and the supernatant was kept for further purification. The pellet was 
resuspended in 10 mL of LanA Start Buffer again. The soluble portions after 
centrifugation (23,700 × g for 20 min at 4 °C) were combined and clarified using 0.45 μm 
syringe filters (Corning), then purified by immobilized metal affinity chromatography 
(IMAC) using a 5 mL HisTrap™ HP nickel affinity column (GE Healthcare Life 
Sciences). The filtered sample was applied to the column and the column was washed 
with 2 column volumes of LanA Buffer 1, followed by 2 - 3 column volumes of LanA 
Buffer 2, and then eluted by 3 column volumes of LanA Elution Buffer. The elution 
fractions were desalted and purified by solid phase extraction (SPE) using a 3 mL 
Vydac® BioSelect™ reversed-phase C4 column. A step gradient of 2 column volumes 
(CV) of 2% solvent B (0.086% TFA in 80% acetonitrile / 20% water) in solvent A (0.1% 
TFA in water), 2 CV of 50% solvent B in solvent A, and 2 CV of 100% solvent B was 
applied for the purification. The fractions were analyzed by MALDI-ToF-MS for the 
desired peptides. The majority of ProcA3.2TEV with Phe26 substituted with pBpa eluted 
in fractions of 50% solvent B in solvent A. (Y.S. Notebook 5 Page 36 – 47). 
        An 18 µL sample that eluted at 50% solvent B was incubated with 0.03 U 
endoproteinase GluC in 50 mM tris buffer at room temperature for 6 h. The mixture was 
quenched with 0.5% (final concentration) TFA, desalted by Zip-Tip and subjected to 
MALDI-ToF-MS (for the spectrum, see Figure 2.11). (Y.S. Notebook 5 Page 46 – 47). 
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Plasmid Characteristic
pET15b amp  for ampicillin resistance, pBR322 origin
pRSFDuet-1 kan  for ampicillin resistance, RSF origin
pCDFDuet-1 aadA  for spectinomycin resistance, CDF origin
Table 2.4 Plasmid vectors used in Chapter 2. 
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a: Ring topology confirmed by tandem mass spectrometry6 and NMR spectroscopy.15 Preparation 
and ring topology elucidation by tandem mass spectrometry for ProcA2.8 was described in this 
chapter.  
b: Products detected in the supernatant of Prochlorococcus MIT9313 by tandem mass 
spectrometry as reported.6 
c: mRNA detected in Prochlorococcus MIT9313 by transcription analysis as reported.6 
d: WT represents “wild type”. Y without further explanations in brackets indicates that the “wild 
type” peptide was used. 
e. The genes encoding ProcAs inserted in the MCS-1 of procM/pRSFDuet-1 
f. Prochlorosins prepared by co-expression in E. coli.  
g. Purified ProcM-modified ProcA peptides generated by co-expression in E. coli. 
 
Table 2.5 Summary of the constructs and purified peptides mentioned in Chapter 2. 
ProcA
Ring 
topology
a
In 
producing 
strain
b
Transcri-
bed
c In pET15b
d
In procM/pRSFDuet-1
e
Pcn
f
purified
g
ProcA1.1 Y Y Y Y (G−1E)
ProcA1.2 Y Y (A−1K) Y(A−1K)
ProcA1.3 Y Y (G−1K)
ProcA1.4 Y Y (G−1E) Y(G−1E)
ProcA1.5 Y Y (A−1K) Y(A−1K)
ProcA1.6 Y Y (WT/G−1R) Y(WT/G−1R)
ProcA1.7 Y Y Y Y (WT/G−1R) Y Y(WT/G−1R)
ProcA2.1 Y Y (WT/Xa) Y (G−1R/G−1E) Y(G−1R/G−1E)
ProcA2.4 Y
ProcA2.5 Y
ProcA2.7 Y
ProcA2.8 Y Y Y (WT/G−1K/G−1K-His6) Y Y(WT/G−1K/G−1K-His6)
ProcA2.11 Y Y Y (WT/Xa/TEV) Y (G−1K) Y Y(G−1K)
ProcA3.2 Y Y(WT/Xa/TEV) Y (TEV) Y Y(TEV)
ProcA3.3 Y Y Y Y (G−1K/G−1E/G−1K-His6) Y Y(G−1K/G−1E/G−1KHis6)
ProcA4.1 Y Y (TEV) Y(TEV)
ProcA4.3 Y Y Y Y (G−1R/G−1E) Y(G−1R)
ProcA4.4 Y Y (G−1E) Y(G-1E)
ProcAs.1 Y Y (G−1K) Y(G−1K)
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CHAPTER 3: HETEROLOGOUS PRODUCTION OF THE 
LANTIBIOTIC ALA(0)ACTAGARDINE IN ESCHERICHIA 
COLI
1
 
 
3.1 INTRODUCTION 
        The majority of lanthipeptides possess antimicrobial activities, and they are called 
lantibiotics. Nisin has been used as a food preservative for more than fifty years without 
significant antibiotic resistance. Therefore, lanthipeptides are a class of promising 
compounds as potential medicinal antibiotics, given that the rising antibiotics resistance 
problem requires the adoption of new scaffolds for new antibiotics. However, most 
elongated lanthipeptides, such as nisin, that have well-known antimicrobial activities ex 
vivo, degrade too fast in the intestine or blood to work as potential drugs.
2
 In contrast, 
globular lanthipeptides with more rigid conformations have higher resistance to protease 
degradation
3
 and thus are expected to have longer life time in the serum, making them 
more promising as drug candidates. Thus far, two lantibiotic derivatives, NAI-107 and 
NVB302 have been evaluated in preclinical studies.
4
 NAI-107 is also known as 
microbisporicin, while NVB302 is derived from actagardine (Figure 3.1). In fact, 
NVB302 has successfully completed a Phase II clinical trial recently. 
 
1
Parts of this chapter have been reproduced with permission from: "Heterologous production of 
the lantibiotic Ala(0)actagardine in Escherichia coli. " Chem. Commun. 2012, 48, 10966-10968, 
published by The Royal Society of Chemistry.  
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         Actagardine is a 19-amino-acid lanthipeptide produced by an actinomycete, 
Actinoplanes garbadinensis. It possesses a globular conformation with an N-terminal 
lanthionine ring and three C-terminal intertwined methyllanthionine rings (Figure 3.1). 
Actagardine possesses potent antimicrobial activity against gram-positive pathogens, and 
is most effective against streptococci and obligate anaerobes. The discovery of the 
compound and preliminary investigation of its antimicrobial activity was reported in 
1976
5-7
 and 1977,
8
 when it was named gardimycin. Twenty years later, the two- and 
Figure 3.1 Biosynthesis pathway of actagardine and its derivatives, with sequence 
alignments of GarA and its homologue, LigA. (A) Structures and biosynthesis of 
actagardine, deoxyactagardine B (DAB), NVB302 and Ala(0)-deoxyactagardine B-Lys. (B) 
Amino acid sequences of the precursor peptides for actagardine (GarA) and DAB (LigA). 
The blue arrow in (B) indicates the proteolytic cleavage site. Amino acid sequences N-
terminally to the arrow are leader peptides, while the sequences C-terminally to the arrow 
are core peptides. Positive residue numbers are used for amino acids in the core peptide 
counting forward from the leader peptide cleavage site. 
Leader peptide Core peptide 
1                                                   19 
B 
A 
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three-dimensional structure of actagardine in solution was determined in a water-
acetonitrile environment.
9,10
  It has been suggested that actagardine, similarly to its 
structural relative mersacidin, binds to lipid II and blocks transglycosylation thus 
inhibiting cell wall biosynthesis. Its activity is not antagonized by vancomycin, which is 
known to bind to the C-terminal D-Ala-D-Ala of the pentapeptide of lipid II during cell 
wall synthesis, suggesting that actagardine interacts with the disaccharide-pyrophosphate 
moiety of lipid II.
11
  
        Actagardine and its derivatives recently entered clinical trials at Novacta 
Therapeutics due to its selectivity against Clostridium difficile, with reduced activity 
against other bacteria in the gut flora, especially anaerobic gram-positive cocci.
4
 
Actagardine was also shown to be stable in simulated gastric fluid. Therefore, it is 
evaluated as a drug candidate treating C. difficile associated diarrhea.
4
 
        The biosynthetic gene cluster of actagardine in Actinoplanes garbadinensis 
ATCC31049 was reported in 2009 (Figure 3.2).
12
 In the cluster, garA encodes the 
precursor peptide, and garM encodes a LanM protein that performs dehydration and 
cyclization on the core peptide. Also present in the cluster is a gene encoding a novel 
luciferase-like monooxygenase GarO that is believed to catalyze the formation of the 
sulfoxide group in actagardine, as postulated based on gene knockout studies.
12
 
Heterologous expression of all genes in the biosynthetic gene cluster of actagardine in 
Streptomyces lividans generated ala(0)-actagardine, which was also reported as an 
antimicrobial compound,
13
 suggesting the protease responsible for the removal of the 
alanine residue N-terminally to actagardine is located outside the biosynthetic gene 
cluster of actagardine.
12
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        Deoxyactagardine B (DAB) is a sequence and structural analogue of actagardine, 
differing only by two residues (V15L and I16V in DAB compared to actagardine, Figure 
3.1). The biosynthetic gene cluster of DAB in Actinoplanes liguriae NCIMB41362 was 
reported in 2010 (Figure 3.2).
14
 Although a luciferase-like monooxygenase (LigO) was 
also present in the DAB biosynthetic gene cluster, actagardine B with a sulfoxide group 
was not detected from A. liguriae NCIMB41362 culture. NVB302, a derivative of DAB 
with a diaminoheptane tail attached semi-synthetically to the C-terminus of the 
lanthipeptide structure, has entered clinical trials for treating C. difficile associated 
diarrhea.
4
 
        To the best of my knowledge, current production of actagardine derivatives follows 
semisynthetic routes
4
 starting from the purification of actagardine or DAB from A. 
garbadinensis or A. liguriae, followed by the chemical addition of the C-terminal 
hydrophilic tail. In contrast, heterologous biosynthesis of actagardine in Escherichia coli 
Figure 3.2 The biosynthetic gene clusters of (A) actagardine and (B) DAB. GarA, 
actagardine precursor peptide; GarM, modification enzyme; GarO, monooxygenase; GarR1, 
response regulator; GarH, transporter permease; GarT, ABC transporter; GarK, response 
regulator kinase; GarR, response regulator sensor. The deoxyactagardine B biosynthetic gene 
cluster possesses analogous genes to the actagardine biosynthesis cluster, while ORF14 
encodes an ABC transporter. Figure was redrawn according to literature results.
16, 18
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has not been reported. Sequence-specific engineering is often more facile for 
heterologously produced compounds compared with analogue generation from the native 
producing strain. As my previous work described in Chapter 2 had shown the success of 
modifying lanthipeptides directly in E. coli by co-expression of the substrate and 
corresponding modification enzymes,
15
 I applied co-expression to the heterologous 
production of actagardine and its derivatives, followed by the affinity purification of 
modified precursor peptides and proteolytic removal of the leader peptides. In this way, I 
aimed to develop an alternative and more convenient route to produce actagardine and its 
derivatives, with advantages in the ease of purification and sequence engineering of 
substrates, while eliminating the need for organic synthesis.    
        Actagardine is the only known lanthipeptide that possesses a sulfoxide group in its 
structure.
3
 It was suggested by gene knock-out studies that the sulfoxide group was 
introduced enzymatically by GarO, the only known luciferase-like monooxygenase in all 
published lanthipeptide biosynthetic gene clusters.
12
 However, GarO had never been 
reconstituted in vitro before the work described in this Chapter. Thus, investigation on 
the formation of the sulfoxide group was envisioned to expand current knowledge on 
lanthipeptide structures and lanthipeptide biosynthetic enzymes. 
 
3.2 RESULTS AND DISCUSSION 
3.2.1 Expression vector construction for GarA, GarM and GarO 
          Actinoplanes garbadinensis ATCC 31049 was grown in GYM and LB liquid 
media and on GYM or oatmeal agar plates. Genomic DNA of Actinoplanes 
garbadinensis ATCC 31049 was extracted from GYM and LB liquid cultures. The genes 
79 
 
encoding GarA and GarO were cloned using a pair of primers (Table 4.1). In contrast, 
garM was cloned using stepwise overlap extension PCR using Phusion polymerase.  
        The garA gene was inserted into multiple cloning site-1 (MCS1) of pRSFDuet-1 
such that the GarA product contained an N-terminal His6-tag, while garM was inserted 
into MCS2 of pRSFDuet-1. Several garA derivatives substituting the garA in MCS1 in 
garM/pRSFDuet-1 were also constructed, including garA-A−1K to introduce a Lys-C 
cleavage site C-terminally to the leader peptide, garA-A−1L/A−2L to introduce two 
leucine residues for proteolytic removal of the leader peptide with Leu aminopeptidase, 
garA-IEGR (in which the nucleotides encoding the four C-terminal residues of GarA 
leader peptide were substituted with codons encoding IEGR residues) to allow Factor Xa 
cleavage, garA-19insK to add a lysine residue C-terminally to the core peptide in order to 
increase the solubility of actagardine, garA-V15L/I16V to mimic the sequence of DAB, 
and garA-V15L/I16V/19insK to mimic NVB302. Negative residue numbers are used for 
amino acids in the leader peptide counting backwards from the leader peptide cleavage 
site, while positive residue numbers are used for amino acids in the core peptide counting 
forward from the leader peptide cleavage site. 
        Two copies of the garO gene were inserted into MCS1 and MCS2 of pCDFDuet-1, 
generating GarO without a His6-tag. Vectors with one garO only in MCS1 of pCDFDuet-
1 that did not encode a His6-tag, were also generated. A pRSFDuet-1 was also prepared 
with garA in MCS1, garM in MCS2, and garO (no attached His6-tag gene) with its own 
T7 promoter, ribosomal binding site, and T7 terminator. The garO gene was also inserted 
in pET28b producing GarO with an N-terminal His6-tag for in vitro protein reconstitution. 
In order to perform protein purification for crystallization attempts, the garM gene was 
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also inserted in pET28b and MCS1 of pRSFDuet-1 to produce GarM with an N-terminal 
His6-tag. 
 
3.2.2 Modification of GarA and GarA derivatives by GarM in E. coli 
        Co-expression of GarM and His6-tagged GarA using the pRSFDuet-1 vector 
successfully generated four-fold dehydrated GarA. The peptide was purified by 
immobilized metal affinity chromatography (IMAC; Ni
2+
) and reversed-phase high-
performance liquid chromatography (RP-HPLC). After lyophilization, 4.2 mg modified 
GarA was obtained from 1 L of culture. Proteolytic removal of the majority of the leader 
peptide with trypsin (cleavage after Arg−5 of the leader peptide) followed by treatment 
with aminopeptidase A8200 to remove residues −4 to −2, generated a product consistent 
with Ala(0)-deoxyactagardine (Figure 3.3A). After incubation with 2-iodoacetamide 
(IAA), no IAA adducts were detected by matrix-assisted laser desorption ionization 
(MALDI) mass spectrometry (MS) (Figure 3.4), suggesting that free cysteines were not 
present in the core peptide.  
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        Ala(0)-deoxyactagardine (Ala(0)-DA) thus produced displayed low solubility. 
NVB302 that is in clinical development contains a C-terminal 1,7-diaminoheptane tail, 
which increases solubility and bioactivity compared with deoxyactagardine.
16
 In order to 
produce a structure similar to NVB302, we substituted Val15 and Ile16 in GarA with Leu 
and Val, respectively, and introduced a lysine residue at its C-terminus, forming GarA-
V15L/I16V/19insK (Figure 3.1) to similarly increase the solubility of Ala(0)-DA 
produced in E. coli. The dehydration and cyclization of this mutant GarA by GarM was 
not affected by these mutations or by the addition of the C-terminal lysine as confirmed 
Figure 3.3 MALDI-MS spectra of GarA and GarA-V15L/I16V/19insK modified by 
GarM in E. coli and treated with trypsin and aminopeptidase A8200 to remove the leader 
peptide. (A) Spectrum of Ala(0)-deoxyactagardine, [M + H]
+
 calculated m/z: 1945.34, 
observed m/z: 1945.68; (B) Spectrum of Ala(0)-DAB-Lys, [M + H]
+
 calc. m/z: 2073.51, 
obs. m/z: 2074.01. 
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by MALDI MS after proteolytic cleavage with trypsin and aminopeptidase (Figure 3.3B). 
The compound produced was termed Ala(0)-DAB-Lys (Figure 3.1). 
        In order to completely remove the leader peptide, such that Ala(0) was no longer 
attached to the deoxyactagardine core peptide, the peptides GarA-A−1K, GarA-
A−1L/A−2L, and GarA-IEGR were co-expressed with GarM using pRSFDuet-1. 
Peptides were purified by Ni-NTA and C4 RP-HPLC. All of these precursor peptides 
were successfully generated with four dehydrations, although GarA-A−1K was obtained 
in very low yield. After treatment with trypsin followed by the addition of 
aminopeptidase A8200, which worked better than leucine aminopeotidase in removing 
the leader peptide in the case of GarA-A−1L/A−2L, deoxyactagardine was generated, but 
Figure 3.4 MALDI-MS spectra of GarM-modified GarA incubated with IAA (blue) and 
without IAA (red) and treated with trypsin. M indicates the fragment of GarM-modified GarA 
after trypsin cleavage (sequence: TIYA-DAB, [M − 4 H2O + H]
+
 calc. m/z: 2393.08, obs. m/z: 
2393.00) 
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the product with Leu(0) attached was still the major product. Factor Xa was not able to 
cleave C-terminally at the arginine residue of IEGR in GarA-IEGR. Instead, it 
preferentially cleaved C-terminally to Arg(−6), generating TIEGR-deoxyactagardine. The 
proteolysis reactions described here were all complete with no starting material peak 
observed in the final reaction mixtures. Given the difficulties to produce DAB I focused 
my efforts on Ala(0)-DAB and its derivatives. 
 
3.2.3 Ring topology confirmation of modifications on GarA derivatives 
        To confirm that the Ala(0)-DAB-Lys product had the correct ring topology, it was 
analyzed by tandem MS indicating a globular structure as no fragments were generated 
from the C-terminal fourteen amino acid region (Figure 3.5). Furthermore, Ala(0)-DAB-
Lys displayed antimicrobial activity against Bacillus subtilis W23, Microccoccus luteus 
Figure 3.5 ESI-MS/MS of GarA-V15L/I16V/19insK modified in E. coli by GarM and 
GarO and treated in vitro with trypsin and aminopeptidase A8200. 
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4698 (Figure 3.6), and Enterococcus faecalis 29212. The MIC of Ala(0)-DAB-Lys 
against E. faecalis was 7.3 M compared to 4.2 M reported for deoxyactagardine and 
actagardine.
12
 Thus, the addition of a C-terminal lysine largely maintained the 
antimicrobial activity of Ala(0)-deoxyactagardine, while significantly increasing 
solubility. 
3.2.4 Modification of GarA and GarA derivatives by GarM and GarO in E. coli 
       Deoxyactagardine is less active than actagardine against some bacterial strains with a 
two-fold increased MIC for inhibition of the growth of M. luteus 4698.
12
 In an attempt to 
produce sulfoxide-containing analogs, co-expression with the monooxygenase GarO was 
pursued. Co-expression of garA/garM/pRSFDuet-1 and garO/pCDFDuet-1 only 
1 2 
A B 
Figure 3.6 Antimicrobial assays of actagardine derivatives. (A) Antimicrobial assays of 
Ala(0)-DAB-Lys modified in E. coli. (1) Nisin, (2) Ala(0)-DAB-Lys from GarA/GarM 
coexpression in  E. coli, (3) negative control containing buffer and proteinases. The applied 
samples in (1) and (2) consisted of 20 L of 100 M stock solutions. (B) Antimicrobial 
activity of Ala(0)-deoxyactagardine and Ala(0)-deoxyactagardine-Lys generated in E. coli 
against M. luteus ATCC 4698. Compounds were produced by incubating His6-GarA and 
His6-GarA-19insK with trypsin and aminopeptidase A8200 to remove the leader peptide. 
Compounds spotted in the wells were: (1) Ala(0)-deoxyactagardine from GarA, final 
concentration (f.c.) 1.87 mg/mL, (2) Ala(0)-deoxyactagardine-Lys from GarA-19insK,  f.c. 
1.96 mg/mL (40L was spotted in each well). 
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produced GarM-modified GarA without oxidation. Therefore, two systems were further 
evaluated in which either the garA/garM/pRSFDuet-1 plasmid was used in combination 
with a pCDFDuet-1 vector containing two copies of garO (2garO/pCDFDuet-1), or the 
garO gene was inserted into the garA/garM/pRSFDuet-1 plasmid (see Experimental 
section for details). His-tagged GarA was purified by IMAC followed by C8 solid phase 
extraction (SPE). The purified product was incubated with trypsin and aminopeptidase to 
remove the leader peptide and the product was analyzed by MALDI-MS. For both 
approaches, the mass of the resulting four-fold dehydrated core peptide was increased by 
Figure 3.7 MALDI-MS spectra of GarA modified by GarM and GarO. (A) Spectrum of 
GarA from co-expression of garA/garM/pRSFDuet-1 with 2garO/pCDFDuet-1 in E. coli, 
followed by trypsin digestion. M indicates GarM-modified GarA treated with trypsin, [M + 
O + Na]
+
 calc. m/z: 2431.06, obs. m/z: 2431.45; (B) product of incubation of GarA-
V15L/I16V/19insK with GarO in vitro and subsequent trypsin digest; [M + O + Na]
+
 calc. 
m/z: 2559.23, obs. m/z: 2559.55; (C) product of incubation of purified Ala(0)-DAB-Lys with 
GarO in vitro, M indicates Ala(0)-DAB-Lys, [M + O + Na]
+
 calc. m/z: 2111.49, obs. m/z: 
2111.77. 
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16 Da (Figure 3.7A and Figure 3.8), consistent with the formation of one sulfoxide group. 
Unfortunately, when the same experiments were performed with GarA-
V15L/I16V/19insK, the GarO-mediated oxidation was incomplete (Figure 3.9), 
suggesting that the additional C-terminal Lys interferes with efficient oxidation in E. coli. 
 
3.2.5 In vitro reconstitution of GarO 
        Actagardine is the only lantibiotic containing a sulfoxide group. To investigate the 
GarO enzymatic activity in vitro, garO was cloned into a pET28b vector. The protein was 
expressed in E. coli with an N-terminal His6-tag, and was purified by IMAC. His6-GarO 
behaved as a monomer in solution as determined by analytical gel filtration 
chromatography (Figure 3.10). Sequence analysis suggests that GarO is a luciferase-like 
Figure 3.8 MALDI-MS spectrum of GarA modified by GarO from co-expression of 
garA/garM/garO/pRSFDuet-1. M indicates GarM-modified GarA with most of the 
leader peptide removed by trypsin (sequence: TIYA-deoxyactagardine, [M + O + Na]
+
 
calc. m/z: 2431.06, obs. m/z: 2431.34; [M + O + K]
+
 calc. m/z: 2447.17, obs. m/z: 
2447.38) 
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monooxygenase that possesses a typical binding domain for flavin mononucleotide 
(FMN). Previous studies on luciferase-like enzymes
17,18
 have shown that reduced FMN 
reacts with molecular oxygen, forming a flavin-hydroperoxide, which is followed by 
transfer of an oxygen atom to the substrate. NAD(P)H then commonly reduces the 
oxidized flavin back to its reduced form. We incubated GarM-modified GarA and GarA-
V15L/I16V/19insK with purified GarO, FMN, and NADH, followed by proteolytic 
removal of the leader peptide as described above. MALDI analysis showed the formation 
of a molecular ion consistent with a single oxidation in the core peptide (Figure 3.7B). 
Substitution of NADH with NADPH resulted in abolishment of the GarO activity. 
 
 
 
Figure 3.9 MALDI-MS spectrum of modified GarA-V15L/I16V/19insK from co-
expression of garA-V15L/I16V/19insK/garM/pRSFDuet-1 and 2garO/pCDFDuet-1. M 
indicates GarM-modified GarA-V15L/I16V/19insK with the leader peptide removed by 
trypsin and aminopeptidase A8200 (sequence: Ala(0)-DAB-Lys, [M + O + Na]
+
 calc. m/z: 
2095.49, obs. m/z: 2095.64; [M + O + Na]
+
 calc. m/z: 2111.49, obs. m/z: 2111.68). 
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        The dehydration and cyclization reactions involved in lantibiotic biosynthesis 
require the presence of the leader peptide, but other tailoring-type transformations such as 
hydroxylation
19
 and oxidative decarboxylation
20
 do not require the leader peptide to be 
attached. To determine whether oxidation by GarO required the leader peptide, the 
enzyme was incubated for 8 h with purified Ala(0)-DAB-Lys, FMN, and NADH. The 
major product was a peptide with m/z of +16 Da (Figure 3.7C). Thus, the leader peptide 
is not required for GarO catalysis, and the C-terminal Lys does not prevent GarO activity. 
The lack of oxidation in E. coli when co-expressing GarA-V15L/I16V/19insK with GarM 
and GarO (Figure 3.9) may therefore be the result of relatively inefficient production of 
GarO. A peak corresponding to the addition of three oxygen atoms was also observed in 
the product of in vitro GarO modification. This product is likely the result of uncoupling 
Figure 3.10  Analysis of His6-GarO by gel filtration chromatography. Peak A corresponds to 
the monomer of His6-tagged GarO.  
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of the formation of the flavin peroxide and the oxygen transfer to the substrate, resulting 
in the formation of hydrogen peroxide or superoxide, which are known general side 
products of in vitro reactions with flavin-dependent monooxygenases.
21
 Hydrogen 
peroxide formation in turn results in non-enzymatic oxidation of the thioether rings.  
 
3.2.6 Overexpression and purification of GarM 
        In order to perform crystallization trials on GarM, the gene encoding GarM was 
cloned into MCS1 of pRSFDuet-1 and pET28b. The protein was expressed in E. coli with 
an N-terminal His6-tag, and was purified by IMAC and gel filtration fast protein liquid 
chromatography purification (FPLC). However, GarM always eluted with an impurity, 
displaying a strong band with lower molecular weight (between 70 kDa to 100 kDa) than 
His6-GarM (114 kDa) on the SDS-PAGE gel of the FPLC fractions. The impurity could 
not be resolved well from His6-GarM either by IMAC or further gel filtration FPLC 
purification. Therefore, the impurity was assumed to be a truncation product. However, 
addition of protease inhibitor before lysis of the cells and to all the buffers throughout the 
whole purification process did not result in improvements. 
 
3.3 SUMMARY AND OUTLOOK 
        Actagardine is a globular lantibiotic which is stable in simulated gastric fluid and 
highly potent against Clostridium difficile, with reduced activity against other bacteria in 
the gut flora. Its derivative NVB302 has already been evaluated in trials for treating C. 
difficile associated diarrhea. In the work described in Chapter 3, Ala(0)actagardine and 
derivatives were heterologously produced in E. coli by co-expression of the substrate 
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peptide, wild-type and mutated GarA, with GarA modification enzymes GarM and GarO. 
The activity of GarO, a luciferase-like monooxygenase that introduces the unique 
sulfoxide group of actagardine, was also investigated in vitro. The work described in 
Chapter 3 also confirmed that the co-expression system can be utilized to introduce 
multiple post-translational modifications, such as the formation of a sulfoxide structure, 
onto lanthipeptides besides dehydration and cyclization. In fact, based on the success of 
co-expression of prochlorosins as described in Chapter 2, the co-expression methodology 
has also been applied to produce multiple other lanthipeptides, including nisin,
15
 
haloduracin,
15
 cinnamycin,
22
 geobacillin,
23
 and cytolysin.
24
 
 
3.4 MATERIALS AND METHODS 
3.4.1 Materials 
All oligonucleotides were purchased from Integrated DNA Technologies. Restriction 
endonucleases, DNA polymerases, and T4 DNA ligase were purchased from New 
England Biolabs. Media components for culturing bacteria were purchased from Difco 
laboratories. Chemicals were purchased from Fisher Scientific or from Aldrich unless 
noted otherwise. Trypsin was purchased from Worthington Biosciences. Aminopeptidase 
A8200 was purchased from Sigma. E. coli DH5α was used as host for cloning and 
plasmid propagation, and E. coli BL21 (DE3) was used as a host for co-expression. 
 
3.4.2 General methods 
Positive residue numbers are used for amino acids in the core peptide counting 
forward starting from the N-terminal residue in the core peptide. Actagardine can be 
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produced with an additional N-terminal alanine in Actinoplanes garbadinensis, and this 
N-terminal alanine residue is numbered Ala(0).
12,13
 We also constructed actagardine 
derivatives with an extra lysine residue located at the C-terminus of GarA generating 
GarA-19insK. Another derivative with Val15 and Ile16 substituted with Leu and Val 
residues and an extra lysine residue attached to the C-terminus was also constructed, and 
this mutant was named GarA-V15L/I16V/19insK. 
All polymerase chain reactions (PCR) were carried out on a C1000™ thermal cycler 
(Bio-Rad). DNA sequencing was performed by ACGT Inc. and the Biotechnology Center 
at the University of Illinois at Urbana-Champaign, using appropriate primers. Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
was carried out on an ultrafleXtreme
TM
 MALDI TOF/TOF system (Bruker Daltonics). 
Liquid chromatography electrospray ionization tandem mass spectrometry (LC/ESI-
MS/MS) was carried out and processed using a Synapt ESI quadrupole TOF Mass 
Spectrometry System (Waters) equipped with an Acquity Ultra Performance Liquid 
Chromatography (UPLC) system (Waters). Fast protein liquid chromatography (FPLC) 
purification was carried out on an Amersham Biosciences/GE Healthcare ÄKTA system. 
 
3.4.3 Genomic DNA extraction of Actinoplanes garbadinensis ATCC 31049 
Actinoplanes garbadinensis ATCC 31049 bacteria were purchased from the 
American Type Culture Collection (ATCC). Lyophilized bacteria were inoculated in 50 
mL of GYM or LB media. The mixtures were shaken at 30 °C and 200 r.p.m. for a week 
with autoclaved glass beads present in the flask and then centrifuged. The Actinoplanes 
garbadinensis ATCC 31049 genomic DNA was extracted from the cell pellet, using Ultra 
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Clean
TM
 Microbial DNA Isolation Kit (MO Bio Laboratories Inc.) or Wizard
®
 Plus SV 
Minipreps kit (Promega), with the Ultra Clean
TM
 kit gaving higher yield. (See Y.S. 
Notebook 5, Page 084). 
 
3.4.4 Construction of pRSFDuet-1 derivatives for garM, garA, and garO 
Attempts to clone garM using terminal forward and reverse primers all failed, 
resulting in either very weak bands or no bands under various conditions using a variety 
of polymerases. The garM gene was therefore cloned by PCR from A. garbadinensis 
ATCC 31049 genomic DNA using stepwise overlap extension PCR (for all primer 
sequences, see Table 3.1): the first round PCR generated fragment GarM_NdeI_1456 
using GarM_NdeI_FLP_Duet-1 and GarM_1456seq_RP primer pair, fragment 
GarM_1117_2074 using GarM_1117seq_FP and GarM_2074seq_RP primer pair, 
fragment GarM_576_2074 using GarM_576seq_FP and GarM_2074seq_RP primer pair, 
and fragment GarM_1689_KpnI using GarM_1689seq_FP and GarM_KpnI_RLP_Duet-1 
primer pair. The second round PCR generated fragment GarM_NdeI_2074 using 
GarM_NdeI_1456 and GarM_1117_2074 megaprimer pair, and fragment 
GarM_576_KpnI using GarM_576_2074 and GarM_1689_KpnI megaprimer pair. The 
third round PCR generated the GarM_NdeI_KpnI full-length product using 
GarM_NdeI_2074 and GarM_576_KpnI megaprimers.  
        AccuPrime
TM
 GC rich polymerase (Invitrogen) was able to amplify full length garM 
by PCR providing sufficient amount of product to conduct digestion and ligation, 
yielding more than Phusion polymerase, Platinum Taq, Platinum Pfu or OneTaq 
polymerase. However, the resulting ligation products showed a large number of point 
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mutations in the amplified region, indicating the low fidelity of AccuPrime
TM
 GC rich 
polymerase, which was considered too low to be used to correctly amplify an insert as 
long as 3 kb like garM. The gene garM, obtained by stepwise overlap extension PCR as 
described above, was inserted into multiple cloning site 2 (MCS2) of the pRSFDuet-1 
vector between the NdeI and KpnI restriction sites for co-expression, and into pET28b 
and pRSFDuet-1 between the EcoRI and HindIII restriction sites for GarM protein 
purification. 
        The garA gene was cloned by PCR from A. garbadinensis ATCC 31049 genomic 
DNA with the GarA_EcoRI_FP_Duet-1 and GarA_HindII_RP_Duet-1 primers, and 
inserted between the EcoRI and HindIII restriction sites of MCS1 in pRSFDuet-1. The 
garA mutant gene GarA-19insK was generated using overlap extension PCR with the 
GarA_EcoRI_FP_Duet-1 and GarA_C+K_RP primers, and the garA/pRSFDuet-1 vector 
as the template. The garA mutant gene GarA-V15L/I16V/19insK was generated using 
overlap extension PCR with the GarA_EcoRI_FP_Duet-1 and GarA_LV_C+K_RP 
primers, and the garA/pRSFDuet-1 vector as the template. The wild type and mutant 
garA genes were individually cloned into MCS1 of the pRSFDuet-1 vector between the 
EcoRI and HindIII restriction sites, with the garM gene already inserted in MCS2. 
Plasmids garA-A−1L/A−2L/garM/pRSFDuet-1 and garA-A−1K/garM/pRSFDuet-1 were 
generated similarly using primers listed in Table 3.1. The sequences of the resulting 
plasmids were confirmed by DNA sequencing.  
          The garO/pCDFDuet-1 plasmid was generated by inserting a garO gene into 
MCS2 of pCDFDuet-1 between the NdeI and XhoI restriction sites, resulting in 
garO/pCDFDuet-1. In order to make 2garO/pCDFDuet-1, one copy of garO was 
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inserted into MCS1 of garO/pCDFDuet-1 between the NcoI and HindIII restriction sites 
resulting in two proteins encoded without His6-tags. In order to purify the garO protein to 
perform in vitro assays, the garO gene was inserted into a pET28b vector between NdeI 
and XhoI sites. In order to construct a vector for three-gene co-expression 
(garA/garM/garO), the garO gene was amplified from garO/pCDFDuet-1 including the 
T7 promoter and lac operator and inserted into garA/garM/pRSFDuet-1 or garA-
V15L/I16V/19insK/garM/pRSFDuet-1 vector between the PacI and AvrII sites. 
(Molecular cloning for garA see Y.S. Notebook 5, Page 84 – 85. Successful 
molecular cloning for garM see Y.S. Notebook 6, Page 43 – 49. Molecular cloning for 
garO see Y.S. Notebook 5, Page 94, Y.S. Notebook 6, Page 7 – 9, 69, 82 – 84, 87 – 88. 
Molecular cloning for garA mutants, see Y.S. Notebook 6, Page 61 – 63, 84). 
 
Table 3.1 Primer sequences for cloning and mutagenesis of garA, garM and garO. 
Primer Name Primer Sequence (5'-3')
GarA_EcoRI_FP_Duet-1 GTA AGT ACG AAT TCG ATG TCT GCT CTC GCC ATC GAG AAG 
GarA_HindIII_RP_Duet-1 ATA ATA TCA AGC TTT CAG CAG GCG CAG ATC ACG GTG
GarA_C+K_RP ATA ATA TCA AGC TTT CAT TTG CAG GCG CAG ATC ACG GTG 
GarA_LV_C+K_RP ATA ATA TCA AGC TTT CAT TTG CAG GCG CAA ACC AGG GTG CCG CAC TCG ATC 
GarM_NdeI_FLP_Duet-1 GTA AGT ACC ATA TGT CAC CGG TTC CTT CAC TCA ATT CCA CCT CGG TAC GCG
GarM_KpnI_RLP_Duet-1 ATA ATA TCG GTA CCT CAG GTC AGC GGC GGC TGC AGC CAG
GarM_576seq_FP GCT GCT CAC CGA CCC CGC CTA C 
GarM_1117seq_FP CCG ATC GAC CTG GAG ACC GTG CTG
GarM_1689seq_FP CGA GTC GGA GAA GCG ACA ACT GCT CG
GarM_2249seq_FP CAT CGT CGA GAC CGT CGG CGC CTA CAG
GarM_303seq_RP GTG ACC ACA GTT TGG TGG ACA ACT CG
GarM_867seq_RP CAT CGT CTC GGC GTA GGC GCG TTC
GarM_1456seq_RP GCA TGA TGT CGT AGG CGT CGG TGA ACC C
GarM_2074seq_RP GCT TGT AGC TGT AGG TCT CCT GGG C
GarM_2616seq_RP GAG TTC GGT GGC GAG CCG GTG CAG
GarM_EcoRI_FLP_Duet-1 GTA AGT ACG AAT TCG ATG TCA CCG GTT CCT TCA CTC AAT TCC ACC TCG GTA CGC G
GarM_HindIII_RLP_Duet-1 ATA ATA TCA AGC TTT CAG GTC AGC GGC GGC TGC AGC CAG
GarO_NdeI_FP_Duet-1 TTA AGT CAC ATA TGG TGC TCA GCG TGC TGG ACC AG
GarO_XhoI_RP_Duet-1 ATA ATA TGC TCG AGT CAG GCC GCC GGG GAT G
GarO_EcoRI_FP TTA AGT CAG AAT TCG ATG CTC AGC GTG CTG GAC CAG
GarO_HindIII_RP ATA ATA TGA AGC TTT CAG GCC GCC GGG GAT G
GarO_NcoI_FP TTA AAT CA CCATGGGC ATG CTC AGC GTG CTG GAC CAG
GarO_T7_PacI_FP TCC AGG CA  TTAATTAA CGAAATTAATACGACTCACTATAGGGG
GarO_AvrII_RP ATA ATA TGC CTA GGT CAG GCC GCC GGG GAT G
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3.4.5 Overexpression and purification of GarM-modified His6-tagged GarA and 
GarA-V15L/I16V/19insK 
E. coli BL21 (DE3) cells transformed with a pRSFDuet-1 vector carrying the genes 
encoding GarM and one of the GarA peptides were shaken at 225 r.p.m. in 2 L of LB 
medium containing 50 mg/L kanamycin at 37 °C until the O.D.600 nm reached 0.6 − 0.8. 
The culture was then induced with 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
and shaken continually at 18 °C for an additional 20 h. (Overexpression and purification 
see Y.S. Notebook 6, Page 50, 53, 54, 64, 66, Notebook 7 Page 32). 
For the co-expression of GarA, GarM and GarO, E. coli BL21 (DE3) cells 
transformed with a pRSFDuet-1 vector carrying garA/garM/garO, or transformed with 
two vectors (one was garA/garM/pRSFDuet-1 or garA-
V15L/I16V/19insK/garM/pRSFDuet-1, while the other was garO/pCDFDuet-1 or 
2garO/pCDFDuet-1) were grown in 2 L of LB medium containing 50 mg/L kanamycin 
and 25 mg/L spectinomycin (spectinomycin was not needed for 
garA/garM/garO/pRSFDuet-1 overexpression) at 37 °C until the O.D.600 nm reached 0.6 − 
0.8. The culture was then induced with 0.2 mM IPTG and shaken continually at 18 °C for 
an additional 30 h with garO/pCDFDuet-1 or 20 h with 2garO/pCDFDuet-1. 
(Overexpression and purification see Y.S. Notebook 6, Page 79, 93 – 94; Y.S. Notebook 
7, Page 4, 33, 35, 63 – 65). 
The induced cells were harvested by centrifugation (11,900 × g for 20 min at 4 °C). 
The cell pellet was resuspended in 20 mL of LanA Start Buffer (20 mM NaH2PO4, pH 
7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol) and lysed by sonication 
(35% amplitude, 4.0 s pulse, 9.9 pause, 15 min). The sample was centrifuged (23,700 × g 
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for 40 min at 4 °C) and the supernatant was kept for further purification. The pellet was 
resuspended in another 20 mL of LanA Start Buffer to obtain any soluble proteins 
remaining in the pellet. Insoluble materials were removed from the combined soluble 
fractions by centrifugation (11,900 × g for 20 min at 4 °C), and the resulting sample was 
clarified using a 0.45 μm syringe filter (Corning). The His6-tagged peptides were then 
purified by immobilized metal affinity chromatography (IMAC) using a 5 mL HisTrap™ 
HP nickel affinity column (GE Healthcare Life Sciences). The filtered sample was 
applied to the column and the column was washed with 2 column volumes of LanA 
Buffer 1 (6 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 500 mM 
NaCl, 0.5 mM imidazole), followed by 2 ~ 3 column volumes of LanA Buffer 2 (4 M 
guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 300 mM NaCl, 30 mM 
imidazole), and then eluted with 3 column volumes of LanA Elution Buffer (4 M 
guanidine hydrochloride, 20 mM Tris, pH 7.5 at 25 °C, 100 mM NaCl, 1 M imidazole).  
The elution fractions were purified by preparative reversed-phase high-performance 
liquid chromatography (RP-HPLC) using a Waters Delta-pak™ C4; 15 µm; 300 Å; 25 × 
100 mm PrepPac
®
 Cartridge. Solvents for the RP-HPLC were solvent A (0.1% TFA in 
water) and solvent B (0.086% TFA in 80% acetonitrile / 20% water). A gradient of 2 - 
100% of solvent B was executed over 45 min at a flow rate of 8 mL/min, and peptides 
were detected by absorbance at 220 nm. The fractions were analyzed by MALDI-TOF-
MS. All the fractions containing the desired product were combined and the organic 
solvents were removed by rotary evaporation, followed by lyophilization overnight. The 
yields of modified GarA and GarA-V15L/I16V/19insK from garA/garM/pRSFDuet-1 
were 4.2 mg and 2.1 mg per liter, respectively, while the yields of modified GarA and 
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GarA-V15L/I16V/19insK from garA/garM/pRSFDuet-1 and garA-
V15L/I16V/19insK/garM/pRSFDuet-1 with 2garO/pCDFDuet-1 were 0.17 mg and 0.74 
mg per liter, respectively. The products were kept at −20 °C for short-term storage and 
−80 °C for long-term storage.  
 
3.4.6 Overexpression and purification of His6-tagged GarO 
E. coli BL21 (DE3) cells transformed with garO/pET28b were shaken at 225 r.p.m. in 
2 L of LB medium containing 50 mg/L kanamycin at 37 °C until the O.D.600 nm reached 
0.6 − 0.8. The culture was then induced with 0.33 mM IPTG and shaken at 18 °C for an 
additional 20 h. (See Y.S. Notebook 6, Page 70). 
The purification steps of GarO were all performed at 4 °C. Induced cells were first 
harvested by centrifugation (11,900 × g for 20 min at 4 °C). The cell pellet was 
resuspended in 20 mL of Start Buffer (20 mM Tris, pH 8.0 at 4 °C, 500 mM NaCl, 10% 
glycerol) and lysed by a high pressure homogenizer (Avestin, Inc.). After centrifugation 
(23,700 × g for 40 min at 4 °C), the supernatant was clarified using a 0.45 μm syringe 
filter (Corning), followed by injection onto a fast protein liquid chromatography (FPLC) 
system (ÄKTA, GE Heathcare Life Sciences), equipped with  a 5 mL HisTrap™ HP 
nickel affinity column (GE Healthcare Life Sciences) pre-charged with Ni
2+
 and pre-
equilibrated with Start Buffer. After loading, the column was washed with Buffer A (20 
mM Tris, pH 8.0 at 4 °C, 1 M NaCl, 30 mM imidazole). His6-GarO was eluted using a 
linear gradient of 0-100% of Buffer B (20 mM Tris, pH 8.0 at 4 °C, 1 M NaCl, 200 mM 
imidazole), over 45 min at a flow rate of 2 mL/min and detection by UV absorbance at 
280 nm. The fractions were analyzed by SDS-PAGE (4 – 20% tris-glycine gel, Bio-Rad). 
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All the fractions containing the desired product were combined and concentrated to 2.5 
mL using an Amicon Ultra-15 Centrifuge Filter Unit (10 kDa MWCO, Millipore). Then 
the buffer of the concentrated protein was exchanged to Start Buffer using a PD-10 
desalting column (GE Healthcare Life Sciences). The concentration of the protein was 
determined by absorbance at 280 nm, and the resulting protein sample was stored at 
−80 °C. (See Y.S. Notebook 6, Page 71 – 75, 81). 
To evaluate the oligomerization state of GarO, purified GarO (Calc. M.W.: 38.3 kDa) 
was injected into the FPLC system equipped with a Superdex 200 (GE Healthcare) 
column pre-equilibrated with Column Buffer (20 mM NaH2PO4, 500 mM NaCl, 10% 
glycerol, pH 8.0 at 4 °C). The protein was eluted at a flow rate of 1 mL/min and proteins 
were detected by UV absorbance at 280 nm. The major peak was eluted with a retention 
time of 78 min, indicating a monomer oligomerization state when compared with 
molecular weight standards (Figure 3.10). (See Y.S. Notebook 6 Page 76 – 78). 
 
3.4.7 Proteolytic removal of GarA leader peptide 
Modified GarA and its mutants were dissolved in water generating 6 mg/mL peptide 
solutions. An aliquot of 10 L of GarA stock solution was incubated with 1 L of trypsin 
solution (0.6 mg/mL) in 50 mM Tris buffer (pH = 8.3) for at least 1 h to remove most of 
the N-terminal portion of the leader peptide. An aliquot of 4 L of aminopeptidase 
A8200 (0.1 Unit/ mL) was then added to the mixture and incubated for at least three 
hours to remove the residual C-terminal portion of the leader peptide. (See Y.S. 
Notebook 6 Page 59, 60, 66 – 68, 85 – 86, 89, 91; Notebook 7 Page 27 – 28, 64). 
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3.4.8 Product evaluation for in vivo coexpression of GarA, GarM and GarO 
For the co-expression of GarA, GarM and GarO in E. coli, the same expression 
procedure was used as described above under “Overexpression and purification of His6-
tagged GarM-modified GarA and GarA-V15L/I16V/19insK”. GarA with four 
dehydrations and one oxygen addition was observed after proteolytic cleavage, regardless 
of whether one-vector (garA/garM/garO/pRSFDuet-1) or two vectors 
(garA/garM/pRSFDuet-1 together with 2garO/pCDFDuet-1) were used (Figure 3.8 and 
Figure 3.7A, respectively). Two-vector co-expression using garA-
V15L/I16V/19insK/garM/pRSFDuet-1 together with 2garO/pCDFDuet-1 generated 
GarA-V15L/I16V/19insK with four dehydrations but incomplete addition of one oxygen 
(Figure 3.9). (See Y.S. Notebook 7 Page 63). 
 
3.4.9 HPLC purification of Ala(0)-DAB-Lys 
The Ala(0)-DAB-Lys generated in the trypsin and aminopeptidase A8200 cleavage 
reaction was purified by analytical RP-HPLC using a Vydac™ C18; 5 µm; 300 Å; 4.6 i.d. 
× 250 mm column. Solvents for RP-HPLC were solvent A (0.1% TFA in water) and 
solvent B (0.086% TFA in 80% acetonitrile / 20% water). A gradient of 0.8-100% of 
solvent B was executed over 50 min at a flow rate of 1 mL/min, and peptides were 
detected by absorbance at 220 nm. The fractions were tested by MALDI-ToF-MS for the 
desired peptides. All the fractions containing the desired fully modified product were 
combined and the solvents were removed by lyophilization overnight. The product was 
kept at −20 °C for short-term storage and −80 °C for long-term storage. (See Y.S. 
Notebook 7 Page 64 – 65). 
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3.4.10 Iodoacetamide treatment of modified His6-GarA and its derivatives to detect 
free cysteines 
An aliquot of 20 L of the trypsin cleavage reaction of GarM-modified GarA or its 
derivatives was mixed with 50 mM Tris-HCl (pH 8.3), 50 mM IAA, and 0.5 mM TCEP. 
The resulting solution was then incubated at room temperature overnight, followed by 
desalting using ZipTipC18 (Millipore) and MALDI-TOF-MS analysis. No 
carboxyamidomethyl (CAM) thiol modification was observed after IAA treatment 
(Figure 3.4), suggesting the cyclization was complete and free cysteine residues were not 
present. (See Y.S. Notebook 6 Page 56). 
 
3.4.11 GarO enzymatic assays 
Activity assays for GarO with dehydrated and cyclized GarA, GarA-
V15L/I16V/19insK, and purified Ala(0)-DAB-Lys were carried out in an assay mix 
containing 50 mM Na2HPO4 (pH 8.0), 0.2 mM FMN, and 0.5 mM NADH. The final 
concentrations of GarA (or its derivatives) and GarO were 75 μM and 10 μM, 
respectively. The reaction mixtures were incubated at room temperature overnight. An 
aliquot of 20 L of the reaction was treated with 1 L of trypsin stock solution (0.6 
mg/mL) before analysis by MALDI-ToF mass spectrometry. When NADH was 
substituted with NADPH, no product was observed after overnight incubation. (See Y.S. 
Notebook 6 Page 76 – 78; Y.S. Notebook 7 Page 15, 25 – 28, 70 – 72). 
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3.4.12 Tandem mass spectrometry analysis of GarO modified Ala(0)-DAB-Lys 
To obtain insights into the site of oxidation, an aliquot of 5 L of GarO-modified 
Ala(0)-DAB-Lys was analyzed by LC/ESI-MS/MS. The trypsin cleavage reaction 
mixture was injected to a BEH C8 column (1.7 μm, 1.0 × 100 mm), and the fully 
modified product was purified by UPLC using a gradient of 3% mobile phase B (0.1% 
formic acid in acetonitrile) to 97% mobile phase B in mobile phase A (0.1% formic acid 
in water) over 12 min. Mass spectra were acquired in ESI positive mode in the range of 
50-2000 m/z. The capillary voltage was 3200 V, and the cone voltage was 40 V. The 
other parameters used were as follows: 120 °C source temperature, 300 °C desolvation 
temperature, 150 L/h cone gas flow, and 600 L/h desolvation gas flow. A transfer 
collision energy of 4 V was used for both MS and tandem MS, while the trap collision 
energy was set to 6 V for MS and 35 V for MSMS. Glu-fibrinopeptide B (Sigma) was 
directly infused as the lock mass. The tandem mass spectra were processed with MaxEnt3 
and analyzed by Protein/Peptide Editor in BioLynx 4.1. The software for analyzing both 
precursor ions and fragment ions was set to report any mass within 0.3 amu of the 
calculated values. Fragments corresponding to b7 and y”14 were observed (Figure 3.5), 
confirming the sulfoxide group was added to the C-terminal intertwined rings. The loss of 
one molecule of H2O was observed during MSMS when collision energy was applied on 
the parent ion. (See Y.S. Notebook 7 Page 74 – 76). 
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3.4.13 Bioactivity assay for deoxyactagardine derivatives 
Bacillus subtilis W23 was inoculated from frozen stock into 5 mL of DSMZ Medium 
1 Nutrient Broth and grown overnight at 37 °C and 250 r.p.m. An aliquot of 100 L of 
overnight culture was inoculated into 20 mL of molten DSMZ Medium 1 Nutrient Agar 
kept at 55 °C, followed by dispensing into a round petri dish. While the bacteria-
containing agar was cooled at room temperature for 0.5 h, 20 L of nisin (100 M), 
GarM-modified GarA-V15L/I16V/19insK treated with trypsin and aminopeptidase 
A8200 (peptide final concentrations: 100 M; other components included 50 mM Tris 
buffer, 0.03 mg/mL trypsin, and 0.1 U/mL aminopeptidase A8200, pH = 8.3), or negative 
control with buffer and proteinases only, was spotted onto the agar (Figure 3.6A). (See 
Y.S. Notebook 7 Page 60 – 61, 66 – 69). 
M. luteus ATCC 4698 was inoculated from frozen stock into 5 mL of Mueller-Hinton 
Broth (MHB) and grown overnight at 37 °C and 250 r.p.m. An aliquot of 100 L of 
overnight culture was inoculated into 20 mL of molten Mueller-Hinton Agar (MHA) kept 
at 42 °C, followed by dispensing into a Nunc OmniTray. While the bacteria-containing 
MHA agar was cooled at room temperature for 1 h, another aliquot of 200 L of 
overnight culture was inoculated into 40 mL of molten MHA kept at 42 °C. The mixture 
was then dispensed onto the solidified layer of MHA. Wells were made by placing a 
sterile 96-well PCR plate in the molten seeded agar. Once the agar was solidified, the 96-
well PCR plate was removed and aliquots of 60 L samples were loaded in wells 
independent from each other by spatial separation. Then the plate was transferred to a 
30 °C incubator and kept in the incubator for 36 h. Both Ala(0)-deoxyactagardine and 
Ala(0)-DAB-Lys displayed antimicrobial activity against M. luteus ATCC4698. It was 
103 
 
noted that the addition of one lysine residue to the C-terminus of deoxyactagardine 
increased the core peptide solubility, as precipitate was observed in the well bottom for 
Ala(0)-deoxyactagardine, but not for the Ala(0)-deoxyactagardine-Lys which was 
generated for comparison (Figure 3.6). (See Y.S. Notebook 6 Page 95). 
To further determine the minimum inhibitory concentration (MIC) of Ala(0)-DAB-
Lys, overnight cultures of Bacillus subtilis W23 in DSMZ Medium 1 Nutrient Broth or 
Enterococcus faecalis 29212 in Brain Heart Infusion Broth (BHI) were inoculated into 
fresh DSMZ Medium 1 Nutrient Broth or BHI, respectively, to generate cell cultures with 
an O.D.600 nm of 0.01. An aliquot of 30 L of purified Ala(0)-DAB-Lys aqueous solution 
was added into 250 L of the cell cultures in a 48-well plate (at final peptide 
concentrations of 60 M, 20 M, 10 M, 5 M, 2.5 M, 1.25 M, 625 nM, 312 nM, 156 
nM, 78 nM, 39 nM, 20 nM, 10 nM, and 0 nM). Every concentration was tested in 
triplicate. The plate was shaken at 30 °C at 250 r.p.m. for 6 h, and the cell density was 
monitored by the plate reader at 600 nm. The MIC of Ala(0)-DAB-Lys against Bacillus 
subtilis W23 in DSMZ Medium 1 Nutrient Broth was 1.20 M. The MIC of actagardine 
and deoxyactagardine against Enterococcus faecalis 29212 were reported to be 4.24 M 
and 4.27 M, respectively.12 In comparison, the MIC of Ala(0)-DAB-Lys generated in 
this work against Enterococcus faecalis 29212 in BHI was 7.28 M. (See Y.S. Notebook 
7, Page 60 – 61, 66 – 69. Bioactivity primary test see Y.S. Notebook 7 Page 42 – 45). 
 
3.4.14 Overexpression and purification of His6-tagged GarM 
        E. coli BL21 (DE3) cells were transformed with garM/pET28b or garM/pRSFDuet-
1 via electroporation. The cells were grown in 2 L of LB medium containing 50 mg/L 
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kanamycin at 37 ˚C until the O.D.600nm reached about 0.6. Then the incubation 
temperature was reduced to 18 ˚C and the culture was induced with 0.1 mM IPTG and 
shaken aerobically continuously for an additional 20 h. The cells were harvested by 
centrifugation (5000 × g for 20 min at 4 ˚C). The cell pellet was resuspended in 20 mL of 
GarM Start Buffer (20 mM Tris, pH 8.0 at 4 ˚C, 1 M NaCl, 10% glycerol) and was 
disrupted by multiple passes through a high pressure homogenizer (Avestin, Inc.). The 
insoluble aggregates and cellular debris were then discarded after centrifugation (15,000 
× g for 30 min at 4 ˚C). The supernatant was passed through 0.45 μm syringe filters 
(Corning), followed by nickel affinity fast protein liquid chromatography (FPLC) 
purification using an Amersham Biosciences/GE Healthcare ÄKTA system. A 5 mL 
HisTrap HP nickel affinity column (GE Healthcare Life Sciences) was connected to the 
FPLC system for the purification at 4 ˚C. Solvents for FPLC were solvent A (GarM Start 
Buffer) and solvent B (GarM Elution Buffer: 20 mM Tris, pH 8.0 at 4 ˚C, 1 M NaCl, 200 
mM imidazole). A gradient of 0-100% of solvent B over 45 min was executed with a 
flow rate of 2 mL/min. Proteins were detected by absorbance at 280 nm and collected in 
4 mL fractions. The fractions were analyzed for purity by Tris-Glycine SDS-PAGE (4-20% 
acrylamide gradient). All the fractions containing the pure desired protein were combined 
and concentrated using an Amicon Ultra-15 Centrifugal Filter Unit (30 kDa MW cut off 
for His6-GarM) to about 2.5 mL. Then the buffer of the concentrated protein was 
exchanged to GarM Final Buffer (20 mM HEPES, pH 7.5 at 4 ˚C, 500 mM NaCl) using 
the FPLC system equipped with a SuperDex 75 self-packed gel filtration column. The 
protein was eluted with a flow rate of 0.6 mL/min. Proteins were detected by absorbance 
at 280 nm and collected in 4 mL fractions. A major impurity with a molecular weight 
105 
 
between 70 kDa and 100 kDa could not be separated from GarM after gel filtration, while 
GarM eluted out mainly as the monomer. The concentration of the protein was 
determined by absorbance at 280 nm, demonstrating protein yields of 9.1 mg/L for His6-
GarM (impurity included). The resulting protein sample was stored at -80 ˚C. (See Y.S. 
Notebook 7 Page 90). 
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Plasmid Characteristic
pRSFDuet-1 kan  for kanamycin resistance, RSF origin
pCDFDuet-1 aadA  for spectinomycin resistance, CDF origin
pET28b kan for kanamycin resistance, pBR322 origin
    garO/pCDFDuet-1
    garM/pET28b
    2garO/pCDFDuet-1
    garA/garM/garO/pRSFDuet-1
    garA/garM/pRSFDuet-1
    garA-A−1K/garM/pRSFDuet-1 
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    garM/pRSFDuet-1
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CHAPTER 4: EFFORTS TOWARDS THE 
INCORPORATION OF NON-CANONICAL AMINO ACID 
RESIDUES INTO LANTHIPEPTIDES 
 
4.1 INTRODUCTION  
        Lantibiotics, as a major subclass of lanthipeptides, have antimicrobial activity 
against a variety of bacterial pathogens. With the rapid development of bioinformatics, an 
increasing number of lanthipeptides has been discovered through genome mining,
1-6
 but 
the potential application of these newly discovered compounds is hindered by their 
unknown functions. Meanwhile, no lantibiotics are currently applied in human therapy 
mainly due to their low metabolic stability and unoptimized physical properties.
7,8
 
Therefore, expansion of the structural diversity of lanthipeptides is highly desired, in 
order to probe their unknown functions, as well as to increase their stability, tune their 
solubility and increase their activity. However, these ribosomally synthesized peptides 
generated from precursor peptides made with 20 canonical amino acids possess limited 
functional groups for such exploration.  
        Chemical synthesis mainly through solid phase peptide synthesis (SPPS) techniques 
is currently a major manufacture technology for peptides containing diversified non-
canonical amino acids (NAAs).
9
 SPPS has been utilized to synthesize up to 100-amino-
acid-long peptides.
10
 Combined with solution-phase chemical synthesis, SPPS has been 
successfully applied in large-scale linear peptide drug synthesis such as Fuzeon®, a 
potent HIV-1 membrane fusion inhibitor.
11
 However, chemical synthesis is most efficient 
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for the synthesis of peptides with less than 20 amino acid residues, as the purification 
becomes more difficult as the length increases.
11
 Cyclic peptide structures such as 
lanthipeptides add metabolic stability but also increase the complexity of the chemical 
synthesis, although successful syntheses have been reported.
12-15
 As an alternative to 
organic synthesis of peptides containing non-canonical amino acids, semisynthesis by 
expressed protein ligation (EPL) has been shown to effectively incorporate NAAs.
16,17
 
Intensive research has also been performed to incorporate NAAs during recombinant 
biosynthesis with the help of natural or evolved tRNA synthetases.
18,19
 Schultz and 
coworkers have engineered the Methanococcus jannaschii tyrosyl-tRNA synthetase 
(MjTyrRS) to conjugate various NAAs to a tyrosyl-tRNACUA
Tyr
 from M. jannaschii that 
recognizes the amber codon, in order to position-specifically incorporate NAAs in vivo.
20-
22
 Tirrell and coworkers have utilized the methionyl-tRNA (Met-tRNA) synthetase to 
incorporate methionine analogues in vivo. In the absence of methionine, methionyl-tRNA 
synthetase was able to incorporate certain methionine analogues recognizing the 
methionine natural codon AUG (Figure 4.1A) in a residue-specific manner in vivo.
23
 
Among all the methionine analogues that the authors tried, L-homopropargylglycine (H-
Hpg-OH) and norleucine presented the highest incorporation efficiency (Figure 
4.1A).
19,24
 Furthermore, engineered pyrrolysyl-tRNA synthetase (PylRS)/tRNACUA
Pyl
 (pylT) 
pairs for orthogonal NAA incorporation were recently developed, which were reported to 
function in rich media.
25-29
 Wild type pyrrolysyl-tRNA synthetase recognizes the TAG 
amber codon and was found in Methanosarcina barkeri but not in E. coli, yeast, or 
mammalian cells. An evolved pyrrolysyl-tRNA synthetase-pylT pair has subsequently 
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been utilized to incorporate diversified L-lysine and L-phenylalanine derivatives with 
aliphatic or aromatic side chains (Figure 4.2) into proteins for various biochemical 
applications.
26,30-33
 
        As shown in Chapters 2 and 3, lanthipeptides can be produced by co-expression of 
the precursor peptide and the corresponding modification enzymes in E. coli, followed by 
in vitro proteolytic removal of the leader peptides and HPLC purification of the modified 
core peptides. The co-expression system was able to produce pure prochlorosins at the 
Figure 4.1 NAAs utilized by the methionyl-tRNA synthetase and prochlorosin sequences. 
(A) Methionine and its analogues utilized by methionyl-tRNA synthetase. (B) Pcn1.1, 1.7, 
Pcn2.8 and Pcn3.3 structures. Methionine residues in Pcn 2.8 and Pcn3.3 are highlighted in 
pink. Residues that were mutated into amber codons for pBpa incorporation are highlighted in 
green 
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level of tens of milligrams per liter, enough for the initiation of prochlorosin biological 
activity investigation. Further evaluation of the biological functions of prochlorosins in 
nature, including in situ monitoring of the localization of prochlorosins and identification 
of molecules interacting with prochlorosins in vivo, requires efficient identification of 
their binding partners in complex environments. Therefore, methods are desired to 
introduce probes, which should be inert and small, and not interfere with the interaction 
of prochlorosins with their targets in nature. One example in this category is the 
photocrosslinking amino acid p-benzoyl-L-Phe (pBpa) that can covalently link to adjacent 
peptide chains under exposure of UV light.
21
 Thus, in the work described in this chapter 
Figure 4.2 Examples of reported NAAs incorporated into proteins by the evolved 
pyrrolysyl-tRNA synthetase-pylT pair. 
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we investigated the incorporation of pBpa at various positions of four prochlorosins 
(Figure 4.1B). 
        Nisin A (Figure 4.3) has been used as a food preservative for over fifty years 
throughout the world without development of significant antimicrobial resistance. 
However, nisin A has never entered clinical trials for application in human therapy, 
mainly because of the low stability of this compound. Nisin A degrades by cleavage at 
dehydrobutyrine 2, dehydroalanine 5 and dehydroalanine 33 residues in a wide pH range 
at room temperature.
34
 The activity of nisin A was also reduced by proteolytic cleavage 
N-terminally at serine 29.
35
 The substitution of dehydroalanine 5 with dehydrobutyrine 
increases nisin’s stability against acid-catalyzed chemical degradation.36 Previous 
research has also shown that the nisin A derivative T2S displayed increased antimicrobial 
activity against certain gram-positive bacteria, and that the M21K mutant possesses 
enhanced activity against several gram-negative bacteria such as Pseudomonas and 
Salmonella spp. Meanwhile M21V and K22T analogs of nisin A displayed higher 
potency against notorious pathogens including Streptococcus agalactiae, Clostridium 
difficile, and Listeria monocytogenes,
37
  and the mutant NisA-I4V/S5F/L6G was reported 
Figure 4.3 Nisin A structure. The residues substituted by amber codons are highlighted in 
green. 
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to inhibit the growth of the nisin-producing strain Lactococcus lactis.
38
 Based on these 
previous studies, several residues, including Thr2, Met21, Lys22, Ser29, Ser33, as well as 
the Ile4/Ser5/Leu6 region, were chosen to expand the structural diversity of nisin A with 
the aim of increased stability and increased bioactivity. Based on the previous success, 
we adopted the evolved tRNA synthetase systems as well as Met-tRNA synthetase to 
expand lanthipeptide structural diversity. 
 
4.2 RESULTS AND DISCUSSION 
4.2.1 Overexpression test with an engineered tyrosyl-tRNA synthetase 
        We obtained the engineered  pDULE-Tyr and pEVOL-Tyr vectors from Professor 
Schultz (the Scripps Research Institute) as a generous gift. The latter was reported to 
perform p-benzoyl-L-phenylalanine (pBpa) incorporation into proteins in rich medium,
39
 
whereas minimal medium is needed for pDULE-Tyr.
21
 Both vectors carry an orthogonal 
tyrosyl-tRNA synthetase (MjTyrRS) / tRNACUA
Tyr
 pair to incorporate pBpa at the position 
encoded by the amber codon TAG. We also constructed a series of 
procA/procM/pRSFDuet-1 plasmids with amber codon mutations in the procA genes, 
including procA1.1-G−1K/F1B, procA1.1-G−1K/F2B, procA1.1-G−1K/F11B, procA1.7-
G−1R/M21B, procA3.3-G−1K/Y15B, and procA3.3-G−1K/A23B (B represents the amber 
codon. Negative residue numbers are used for amino acids in the leader peptide counting 
backwards from the leader peptide cleavage site, i.e. the glycine residue immediately N-
terminal to the cleavage site is −1 and when substituted by a lysine residue the mutant is 
denoted as G−1K). E. coli BL21 (DE3) cells were co-transformed with the pDule-Tyr or 
pEVOL-Tyr vector, and a procA/procM/pRSFDuet-1 vector carrying a TAG codon in the 
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procA gene for co-expression. However, no reproducible products containing pBpa were 
obtained from the overexpression tests utilizing the aforementioned vectors.  
        ProcA1.1G−1K_F1B and ProcA1.1G−1K_F11B appeared to show the desired 
products by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI MS) after proteolytic cleavage, but further investigation of these fragments by 
tandem MS did not generate the expected fragmentation for modified Pcn1.1. Other 
constructs did not generate fragments with m/z values that were consistent with 
calculated values. The pBpa was successfully incorporated into ProcA3.2TEV after 
mutating the codon of Phe26 to an amber stop codon, as shown in Chapter 2, but trials 
with other ProcAs were not successful thus far. Prof. Mehl from Franklin and Marshall 
College also tried to use their tRNA/tRNA synthetase pair encoded in an engineered 
pDule vector to incorporate pBpa into Pcn3.2 by using the procA3.2TEV-
F26B/procM/pRSFDuet-1 vector, but has obtained no success thus far, with only 
truncation products observed in MALDI MS, suggesting the introduced amber codon was 
read as a stop codon. 
 
4.2.2 Overexpression test with an engineered methionyl-tRNA synthetase 
        Endogenous methionyl-tRNA synthetase was utilized to incorporate H-Hpg-OH to 
introduce an alkyne group into prochlorosins. Peptides ProcA1.7-G−1E, ProcA2.8 and 
ProcA3.3-G−1K were chosen as the templates as the ring topology of prochlorosin (Pcn) 
1.7, 2.8 and 3.3 has been determined (Figure 4.1B),
1
 and they all possess methionine 
(Met) residues. Pcn1.7 has a Met within a methyllanthionine ring, and Pcn2.8 contains a 
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Met between two lanthionine rings. Pcn3.3 has a large methyllanthionine ring wrapping a 
smaller methyllanthionine ring, with the larger ring containing one Met (Figure 4.1B).  
        A methionine auxotrophic E. coli strain and M9 minimal media supplemented with 
an amino acid mixture were utilized for overexpression. The full procedure for the 
incorporation is described in the Materials and Methods section. For proof of concept, the 
less costly NAA norleucine (Nle) was chosen, which was successfully incorporated into 
ProcM-modified ProcA1.7-G−1E, ProcA2.8, and ProcA3.3-G−1K. Subsequently, H-
Hpg-OH was also successfully incorporated into the fully modified core peptides of 
ProcA2.8 and ProcA3.3-G−1K as confirmed by MALDI MS (Figure 4.4). No ions 
corresponding to methionine incorporation into the ProcA1.7-G−1E core peptide were 
observed in the MALDI mass spectra. One experimental difficulty in these experiments is 
Figure 4.4 MALDI-MS spectra of incorporation of Hpg into (A) ProcA2.8, and (B) Proc3.3-
G−1K. M indicates the linear ProcA fragment containing intact core peptide, generated by 
GluC cleavage.  
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that the calculated m/z value of a peptide containing Hpg and one sodium adduct is the 
same m/z as that of a peptide with the incorporation of methionine instead of Hpg. As 
wild type methionyl-tRNA synthetase was utilized, it is possible to have methione 
incorporated if a small amount of Met was present in the final media supplemented with 
H-Hpg-OH, or if the Met pool in the cells had not been completely depleted prior to 
adding H-Hpg-OH. However, various pre-incubation periods between the medium 
change and induction (see Materials and Methods for a detailed description of the 
incorporation procedure) ranging from 15 min to 30 min did not result in any difference 
regarding the peak intensity ratio of the fragment with only Hpg incorporated and its +22 
Da peak. As the pre-incubation step was desired for the bacteria to consume the residual 
methionine, elongated pre-incubation time was expected to reduce any methionine-
incorporated product. Thus, our results suggest that the +22 Da peak shown in Figure 4.4 
was more probably arising from a sodium adduct of the Hpg incorporated peptide instead 
of methionine incorporation. 
         The NAAs that can be utilized efficiently by wild-type methionyl-tRNA synthetase 
are limited to norleucine, Hpg, and azidohomoalanine (Aha) (Figure 4.1A),
40
 with the 
latter two expensive (L-azidohomoalanine: $1600/g; L-homopropargylglycine: $1200/g, 
as listed by their major suppliers), considering at least 200 mg of the starting material is 
required for 1 L overexpression to obtain at most 3 mg of modified precursor peptide. 
Therefore, methionyl-tRNA synthetase proved not to be ideal for NAA incorporation in 
large scale lanthipeptide production. 
 
 
117 
 
4.2.3 Overexpression test with an engineered pyrrolysyl-tRNA synthetase 
        We constructed six nisA/nisB/pRSFDuet-1 mutants with the codon for one amino 
acid residue in the NisA core peptide substituted by an amber codon, including nisA-T2B, 
nisA-I4V/S5B/L6G, nisA-M21B, nisA-K22B, nisA-S29B, and nisA-S33B. A 
nisC/tRNA/pCDFDuet-1 was constructed per Professor Liu’s (Texas A&M University) 
suggestions, with a higher copy number of pyrrolysyl-tRNA CUA
Pyl
 expected to lead to 
higher levels of incorporation. A pEVOL-pylT-mmPylRS(2X)-N346A/C348A vector was 
generously provided by Professor Liu, which contained one copy of pyrrolysyl-tRNA 
(pylT) under the control of a constitutive proK promoter, and two copies of the 
engineered pyrrolysyl RNA synthetase (mmPylRS-N346A/C348A), one of which is under 
the control of a constitutive glnS promoter while the other is controlled by an arabinose 
inducible araBAD promoter. E. coli BL21 (DE3) cells containing the pEVOL-pylT-
mmPylRS(2X)-N346A/C348A vector were co-transformed with the nisA/nisB/pRSFDuet-1 
mutant plasmids and nisC/tRNA/pCDFDuet-1 for co-expression.  
        Incorporation of 3-trifluoromethyl-L-phenylalanine (L-Phe(3-CF3)-OH) was 
attempted with NisA-T2B, I4V/S5B/L6G, K22B and S29B, while incorporation of 3-
methyl-L-phenylalanine (L-Phe(3-Me)-OH) was tried with NisA-S29B and S33B. Co-
expression of NisA amber mutants, NisB and NisC with L-Phe(3-Me)-OH present in the 
medium as the NAA source produced only truncation products where the introduced 
amber codon was recognized only as a stop codon.  Co-expression in the presence of L-
Phe(3-CF3)-OH  generated products containing the NAA, with the desired peptide 
detected as the major peak in MALDI-MS analysis of NisA-I4V/S5B/L6G after Ni-NTA 
purification (Figure 4.5). Similarly ions were observed corresponding to successful 
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incorporation into NisA-K22B and S29B in MALDI spectra after Ni-NTA purification 
(Figure 4.6). Noteworthy, NisA-I4V/S5B/L6G containing L-Phe(3-CF3)-OH possessed 6 
dehydrations out of 7 expected dehydrated residues (Figure 4.5), NisA-K22B displayed  6 
dehydrations out of 8 anticipated dehydrated residues (Figure 4.6A), while NisA-S29B 
was dehydrated 8 times out of 8 proposed dehydrated residues (Figure 4.6B), as indicated 
by MALDI MS. Truncation products with the introduced amber codon functioning as a 
stop codon dominated in the Ni-NTA elution fractions of NisA-T2B, K22B and S29B. 
Use of minimal medium and lysogeny broth (LB) medium resulted in no significant 
Figure 4.5 MALDI-MS spectra of the incorporation of L-Phe(3-CF3)-OH into NisA-
I4V/S5B/L6G. (A) M9 medium. (B) LB medium. M indicates the linear NisA-
I4V/S5B/L6G fragment containing intact core peptide, generated by trypsin cleavage. NAA 
represents L-Phe(3-CF3)-OH residue. 
NAA 
NAA 
NAA 
NAA 
NAA 
NAA 
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differences in relative ratios of truncation products and incorporated modified products 
(Figure 4.5), although cells in LB medium generally grew faster than in the minimal 
medium.  
        Among the L-Phe(3-CF3)-OH incorporation trials with NisA mutants, truncation 
products in which the amber codon was recognized as a stop codon were observed for 
most of the constructs together with L-Phe(3-CF3)-OH incorporated products. The NisA-
S29B truncation product showed up to 7 dehydrations out of 7 proposed dehydrated 
residues (Figure 4.7), as indicated by MALDI MS. Per suggestion of Prof. Liu, 
minimizing the number of plasmids is beneficial to maintain the health of the E. coli. 
Figure 4.6 MALDI-MS spectra of the incorporation of L-Phe(3-CF3)-OH into (A) NisA-
K22B and (B) NisA-S29B. M indicates the linear fragment containing intact core peptide, 
generated by trypsin cleavage. NAA represents L-Phe(3-CF3)-OH residue. 
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However, co-transformation or co-expression of wild type nisA/nisB/nisC/pRSFDuet-1 
and pEVOL-pylT-mmPylRS(2X)-N346A/C348A always resulted in limited cell growth. 
Thus the two-plasmid strategy was not further pursued. 
 
4.3 SUMMARY AND OUTLOOK 
                 Non-canonical amino acids (NAAs) can expand structural diversity of peptide-
based natural products, introduce probes for investigation of peptide activity, and modify 
biophysical properties of peptides for drug development. In Chapter 4, endogenous 
methionyl-tRNA synthetase and an evolved M. jannaschii tyrosyl-tRNA synthetase 
Figure 4.7 MALDI-MS spectrum of the truncation product from NisA-S29B during co-
expression trial to incorporate L-Phe(3-CF3)-OH. M* indicates the linear fragment containing 
the truncated core peptide with the introduced amber codon serving as the stop codon, 
generated by trypsin cleavage. 
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(MjTyrRS)/tyrosyl-tRNACUA
Tyr
 pair were utilized in trials to incorporate Hpg and pBpa into 
modified ProcAs, respectively. Similar to a recent report on the production of lichenicidin 
in E. coli containing NAAs,
41
 general success was observed using methionyl-tRNA 
synthetase to incorporate Hpg. An engineered pyrrolysyl-tRNA synthetase/tRNA CUA
Pyl
 
(pylT) pair was adopted for trials to incorporate L-Phe(3-CF3)-OH into dehydrated and 
cyclized NisA, with the NAA incorporation observed in certain NisA mutants. Further 
optimization is needed and will be pursued by graduate student Ms. Nidhi Kakkar in our 
laboratory. 
 
4.4 MATERIALS AND METHODS 
4.4.1 Materials 
       L-Homopropargylglycine (H-Hpg-OH) was purchased from Chiralix in the 
Netherlands. 3-Trifluoromethyl-L-phenylalanine (L-Phe(3-CF3)-OH) and 3-methyl-L-
phenylalanine (L-Phe(3-Me)-OH) were purchased from Chem-Impex International, Inc. 
All oligonucleotides were purchased from Integrated DNA Technologies. Restriction 
endonucleases, DNA polymerases and T4 DNA ligase were purchased from New 
England Biolabs or Invitrogen. Media components for bacterial cultures were purchased 
from Difco laboratories. All other chemicals were purchased from Fisher Scientific or 
from Aldrich unless noted otherwise. Endoproteinase GluC, LysC, and trypsin were 
purchased from Roche Biosciences or Worthington Biosciences. Factor Xa protease was 
purchased from New England Biolabs. E. coli DH5α was used as the host for cloning and 
plasmid propagation. E. coli BL21 (DE3) and methionine auxotrophic T7 express crystal 
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competent E. coli (NEB) were used as the hosts for co-expression. Vectors pDULE-Tyr 
and pEVOL-Tyr were obtained from Prof. Peter Schultz at the Scripps Research Institute. 
pEVOL-pylT-mmPylRS(2X)-N346A/C348A was obtained from Prof. Wenshe Liu at Texas 
A&M University. Vectors procA/procM/pRSFDuet-1, nisA/nisB/pRSFDuet-1 and 
nisC/pACYCDuet-1 were constructed previously,
42
 and 
nisA_I4V_S5B_L6G/nisB/pRSFDuet-1 was provided by Neha Garg of our laboratory. 
 
4.4.2 General methods 
        All polymerase chain reactions (PCR) were carried out on a C1000™ thermal cycler 
(Bio-Rad). DNA sequencing was performed by ACGT Inc. and the Biotechnology Center 
at the University of Illinois at Urbana-Champaign, using appropriate primers. Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) 
was carried out on a Voyager-DE-STR (Applied Biosystems). Liquid chromatography 
electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) was carried out and 
processed using a Synapt ESI quadrupole ToF Mass Spectrometry System (Waters) 
equipped with an Acquity Ultra Performance Liquid Chromatography (UPLC) system 
(Waters).  
 
4.4.3 Construction of procA/procM/pRSFDuet-1 mutants containing an amber codon 
        The amber codon TAG was introduced into procA of different 
procA/procM/pRSFDuet-1 vectors, generating co-expression vectors encoding ProcA1.1-
G−1K/F1B, ProcA1.1-G−1K/F2B, ProcA1.1-G−1K/F11B, ProcA1.7-G−1R/M21B, 
ProcA3.3-G−1K/Y15B, and ProcA3.3-G−1K/A23B. The mutants were generated using 
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overlap extension PCR with the procA/procM/pRSFDuet-1 vector as the template. 
Mutated procA genes were introduced into multi cloning site 1 (MCS1) of the 
procM/pRSFDuet-1 vector through digestion and ligation. The general PCR, digestion 
and ligation procedures were the same as described in Chapter 2. The primer sequences 
are listed in Table 4.1. (Y.S. Notebook 5 Page 48 – 51). 
 
4.4.4 Incorporation of para-benzoyl phenylalanine (pBpa) in ProcA 
         E. coli BL21 (DE3) cells transformed with a pDule-Tyr vector or pEVOL-Tyr, and a 
mutated procA/procM/pRSFDuet-1 vector were grown overnight at 37 °C in 5 mL of 
supplemented GMML medium (glycerol minimal medium, supplemented with metals 
and 18-amino-acid solution; for components, see ref. 
21,43
) containing 50 mg/L 
kanamycin and 12.5 mg/L tetracycline. An aliquot of 1 mL overnight culture was 
inoculated into 50 mL of fresh supplemented GMML medium. The culture was shaken at 
Primer Name Primer Sequence (5'-3')
ProcA1.1_EcoRI_FP GGT GCG AGG AAT TCG ATGAAAAAGCGACTCAACAAT
ProcA1.1_NotI_RP AAG CGG CCG CTC AGC ACA CAT TGA TAG
ProcA1.1G-1K_F1B_FP GGT GTG GCT GGG AAA TAG TTC TGT GTG CAG GG
ProcA1.1G-1K_F1B_RP CCC TGC ACA CAG AAC TAT TTC CCA GCC ACA CC
ProcA1.1G-1K_F2B_FP GGT GTG GCT GGG AAA TTT TAG TGT GTG CAG GG
ProcA1.1G-1K_F2B_RP CCC TGC ACA CAC TAA AAT TTC CCA GCC ACA CC
ProcA1.1G-1K_F11B_FP GCA GGG TAC TGC TAA CCG TTA GAC TAT CAA TGT GTG C
ProcA1.1G-1K_F11B_RP GCA CAC ATT GAT AGT CTA ACG GTT AGC AGT ACC CTG C
ProcA1.7_EcoRI_FP GGT GCG AGG AAT TCG ATG AAG CAT AGA CAA CTA AAT CTG
ProcA1.7M21B_NotI_RP ATA ATA TCG CGG CCG CTC AGC ACT ATT TCC CCA C
ProcA3.3_EcoRI_FP GGT GAG TGG AAT TCG ATG TCA GAA GAA CAA CTC AAG GC
ProcA3.3_NotI_RP ATA ATT TAG CGG CCG CCT ATG CGC GGC
ProcA3.3_Y15B_FP CAC GGC TGG ATG TTA GGG CGG GAC CAA AAT G
ProcA3.3_Y15B_RP CAT TTT GGT CCC GCC CTA ACA TCC AGC CGT G
ProcA3.3_A23B_NotI_RP ATA ATT TAG CGG CCG CTC ACT AGC GGC ACA TTT TG
Table 4.1 Primer sequences for cloning and mutagenesis of procAs. 
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37 °C until the O.D.600nm reached 0.5, then pBpa dissolved in 1 M NaOH was added to 
the culture to obtain a final concentration of 1 mM pBpa. After shaking for 0.5 h, the 
culture was induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
shaken continually at 18 °C for an additional 20 h. The induced cells were harvested by 
centrifugation (11,900 × g for 20 min at 4 °C). The cell pellet was resuspended in 10 mL 
of LanA Start Buffer and lysed by sonication (35% amplitude, 4.0 s pulse, 9.9 s pause, 15 
min). The cell lysate was centrifuged (23,700 × g for 40 min at 4 °C) and the supernatant 
was kept for further purification. The pellet was resuspended in 10 mL of LanA Start 
Buffer again. The soluble portions after centrifugation (23,700 × g for 20 min at 4 °C) 
were combined and clarified using 0.45 μm syringe filters (Corning), then purified by 
immobilized metal affinity chromatography (IMAC) using a 1 mL HisTrap™ HP nickel 
affinity column (GE Healthcare Life Sciences). The filtered sample was applied to the 
column and the column was washed with 2 column volumes of LanA Buffer 1, followed 
by 2 - 3 column volumes of LanA Buffer 2, and then eluted by 3 column volumes of 
LanA Elution Buffer. The elution fractions were desalted and purified by solid phase 
extraction (SPE) using a 3 mL Vydac® BioSelect™ reversed-phase C4 column. A step 
gradient wash and elution using 2 column volumes (CV) of 2% solvent B (0.086% TFA 
in 80% acetonitrile / 20% water) in solvent A (0.1% TFA in water), 1 CV of 50% solvent 
B in solvent A, 1 CV of 100% solvent B and 1 CV of acetonitrile was applied for the 
purification. The fractions were tested by MALDI-ToF MS for the desired peptides. The 
majority of the desired peptides eluted in fractions of 50% solvent B in solvent A. (Y.S. 
Notebook 5 Page 52 – 59, 67 – 68). 
        An 10 µL aliquot of cell lysate in LanA Start Buffer after sonication was incubated 
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with 0.03 U endoproteinase GluC in 50 mM HEPES buffer (pH 7.5) at room temperature 
for 6 h. The mixture was quenched with 0.5% (final concentration) TFA, zip-tipped and 
subjected to MALDI-ToF MS. (Y.S. Notebook 5 Page 68 – 69). 
 
4.4.5 Incorporation of H-Hpg-OH using methionyl-tRNA synthetase 
                 Methionine auxotrophic E. coli cells were transformed with a mutated 
procA/procM/pRSFDuet-1 vector. Modified M9aa starter culture
44
 inoculated with 
methionine auxotrophic E. coli was incubated at 37 °C overnight. An aliquot of 50 mL 
M9aa medium inoculated with 1 mL of the starter culture was grown at 37 °C to O.D.600 
0.55. The culture was centrifuged at 6,500 × g for 10 min and washed with 0.9% aqueous 
NaCl 3 times. The pellet was divided into two halves and each pellet was resuspended in 
1 L M9aa medium without methionine, and shaken at 37 °C for 20 min. Then the two 
cultures were cooled on ice for 10 min, supplemented with 300 g/mL H-Hpg-OH 
(O.D.600 = 0.7) or 200 g/mL methionine (O.D.600 = 0.5) as a control experiment, and 
induced with 0.2 mM IPTG. The cultures were shaken at 18 °C for 20 h before harvesting. 
(Y.S. Notebook 6 Page 40 – 42, 55). 
 
4.4.6 Construction of nisA/nisB/pRSFDuet-1 mutants and nisC/tRNA/pCDFDuet-1 
containing an amber codon 
        The amber codon TAG was introduced into nisA/nisB/pRSFDuet-1 vector at 
different positions of nisA, generating co-expression vectors encoding NisA-T2B, NisA-
M21B, NisA-K22B, NisA-S29B, and NisA-S33B. The mutants were generated using 
QuickChange PCR with the nisA/nisB/pRSFDuet-1 vector as the template. The primer 
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sequences are listed in Table 4.2. The PCR mixture included 1× Phusion HF buffer (New 
England BioLabs), dNTP mixture (2 mM each), primers (stock solution 100 M each, 
final concentration 2 M each), DMSO (4%, v/v), template plasmid 
nisA/nisB/pRSFDuet-1 (~ 20 ng) and Phusion High-Fidelity DNA Polymerase (0.02 
U/L). The PCR amplification was performed by thirty cycles of denaturing (98 °C for 
10 s), annealing (57.5 °C for 30 s), and extending (72 °C for 150 s). The product was 
purified by QIAquick PCR Purification Kit (QIAGEN). An aliquot of the purified PCR 
product was mixed with 2 L of 10x NEBuffer 4 and 1 L of DpnI (stock solution 
20,000 U/mL, New England Biolabs), followed by incubation at 37 °C for 1 h. DpnI was 
heat inactivated by incubation at 80 °C for 20 min. An aliquot of 5 L of the resulting 
solution was used for E. coli DH5 heat shock transformation. (Y.S. Notebook 7 Page 78 
– 80). 
          One copy of nisC was inserted into MCS2 of pCDFDuet-1 vector between BglII 
and XhoI restriction sites through PCR amplification, digestion, and ligation using 
nisC/pACYCDuet-1 as the PCR template. In order to increase the copy number presented 
in the co-expression host cells, one copy of pyrrolysyl-tRNA (pylT) was introduced into 
MCS1 of the constructed nisC/pCDFDuet-1 between BamHI and NotI restriction sites, 
using the pEVOL-pylT-mmPylRS(2X)-N346A/C348A vector as the PCR template. The 
general PCR, digestion and ligation procedures were the same as described in Chapter 2. 
The primer sequences are listed in Table 4.2. (Y.S. Notebook 9 Page 3 – 4). 
127 
 
 
4.4.7 Incorporation of non-canonical amino acids in NisA 
         E. coli BL21 (DE3) electro competent cells baring pEVOL-pylT-mmPylRS(2X)-
N346A/C348A were co-transformed with mutated plasmids nisA/nisB/pRSFDuet-1 and 
nisC/tRNA/pCDFDuet-1. Single colonies were picked and inoculated into 5 mL of 
modified M9
43
 or LB culture containing 50 mg/L kanamycin, 8.3 mg/L spectinomycin, 
and 8.3 mg/L chloramphenicol. An aliquot of 2 mL of the overnight culture was 
inoculated into 100 mL of LB or supplemented M9 medium. The culture was shaken at 
37 °C until the O.D.600nm reached 0.5, then L-Phe(3-CF3)-OH or L-Phe(3-Me)-OH 
dissolved in 1 M NaOH solution (for solubility) was added to the culture to obtain a final 
concentration of 2 mM. The culture was immediately neutralized with 5 M HCl to obtain 
pH ~ 7.5. Arabinose (stock solution concentration: 20%) was also added to obtain a final 
concentration of 0.2%. After shaking for 0.5 h, the culture was induced with 0.3 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and shaken continually at 18 °C for an 
Primer Name Primer Sequence (5'-3')
proK_BamHI_FP ATA ATA TGG GAT CCG TGT GCT TCT CAA ATG CCT GAG GCC
tRNA_NotI_RP ATA ATA TGG CGG CCG CCA TGC AAA AAA GCC TGC TCG TTG 
NisA_T2B_FP CAG GTG CAT CAC CAC GCA TTT AGA GTA TTT CGC TAT G 
NisA_T2B_QRP GCG TGG TGA TGC ACC TGA ATC TTT CTT CG
NisA_M21B_FP GAG CTC TGA TGG GTT GTA ACT AGA AAA CAG CAA CTT G 
NisA_M21B_QRP GTT ACA ACC CAT CAG AGC TCC TGT TTT ACA ACC
NisA_K22B_FP CTC TGA TGG GTT GTA ACA TGT AGA CAG CAA CTT GTC 
NisA_K22B_QRP CAT GTT ACA ACC CAT CAG AGC TCC TGT TTT AC
NisA_S29B_FP GAA AAC AGC AAC TTG TCA TTG TTA GAT TCA CGT AAG C 
NisA_S29B_QRP ACA ATG ACA AGT TGC TGT TTT CAT GTT ACA ACC
NisA_S33B_FP GTC ATT GTA GTA TTC ACG TAT AGA AAT AAA AGC TTG CGG C 
NisA_S33B_QRP CGT GAA TAC TAC AAT GAC AAG TTG CTG TTT TC
NisC_T7_PacI_FP TCC AGG CAT TAA TTA ACG AAA TTA ATA CGA CTC ACT ATA GGG G 
NisC_AvrII_RP ATA ATA TGC CTA GGT CAT TTC CTC TTC CCT CCT TTC
Table 4.2 Primer sequences for cloning and mutagenesis of nisA, nisC and pylT. 
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additional 20 h. The induced cells were harvested by centrifugation (11,900 × g for 20 
min at 4 °C). The cell pellet was resuspended in 10 mL of LanA Buffer 1 and lysed by 
sonication (35% amplitude, 4.0 s pulse on, 9.9 s pause, 15 min). The soluble portion after 
centrifugation (23,700 × g, 20 min, 4 °C) was clarified using 0.45 μm syringe filters 
(Corning), then purified by immobilized metal affinity chromatography (IMAC) using a 1 
mL HisTrap™ HP nickel affinity column (GE Healthcare Life Sciences). The filtered 
sample was applied to the column and the column was washed with 2 column volumes 
(CV) of LanA Buffer 1, followed by 2 - 3 CV of LanA Buffer 2, and then eluted with 3 
CV of LanA Elution Buffer. The elution fractions were desalted and purified by solid 
phase extraction (SPE) using a 3 mL Vydac® BioSelect™ reversed-phase C4 column. A 
step gradient of 2 CV of 2% solvent B (0.086% TFA in 80% acetonitrile / 20% water) in 
solvent A (0.1% TFA in water), 1 CV of 50% solvent B in solvent A, 1 CV of 100% 
solvent B, and 1 CV of acetonitrile was applied for the purification. The fractions were 
tested by MALDI-ToF MS for the desired peptides. The majority of peptides were eluted 
in fractions of 50% solvent B in solvent A (Y.S. Notebook 9 Page 7 – 9).  
        An 18 µL sample of lyophilized 50%-solvent B-eluted fraction was incubated with 
0.6 mg/mL trypsin in 50 mM tris buffer (pH 8.0) at room temperature for 0.5 h. The 
mixture was zip-tipped and subjected to MALDI-ToF MS. (Y.S. Notebook 9 Page 10). 
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